tyrosine has been researched along with eptifibatide in 248 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 42 (16.94) | 18.2507 |
| 2000's | 175 (70.56) | 29.6817 |
| 2010's | 29 (11.69) | 24.3611 |
| 2020's | 2 (0.81) | 2.80 |
| Authors | Studies |
|---|---|
| Tcheng, JE | 4 |
| Anderson, KM; Coller, BS; Weisman, HF | 1 |
| Verheugt, FW | 1 |
| Gawaz, M; Neumann, FJ; Schömig, A | 1 |
| Moliterno, DJ; Steinhubl, SR | 1 |
| Adgey, AA | 2 |
| Ferguson, JJ; Lau, TK | 1 |
| Clem, JR; Falls, S | 1 |
| Lincoff, AM | 1 |
| Kleiman, NS; Ramanathan, A | 1 |
| Kleiman, NS | 1 |
| Alexander, JH; Harrington, RA | 1 |
| Bates, ER | 1 |
| Hensley, S | 1 |
| Greenbaum, AB; Harrington, RA; Hudson, MP; Ohman, EM | 1 |
| Al-Mousa, EN; Arshad, MN; Campsey, M; Gandhi, R; Gibson, CM; Marble, SJ; Mattson, S; Mesley, R; Moynihan, JL; Murphy, S; Ryan, KA; Swanson, J | 1 |
| Kaluza, G; Kleiman, NS; Mazur, W | 1 |
| Colombo, A; Dangas, G | 1 |
| Hillegass, WB; Newman, AR; Raco, DL | 1 |
| Holmes, MB; Schneider, DJ; Sobel, BE | 1 |
| Chanu, B | 1 |
| Phillips, J; Stouffer, GA; Subbarao, VD | 1 |
| Abbottsmith, CW; Broderick, TM; Hattemer, C; Kereiakes, DJ; Lacock, P; Mueller, M; Roth, EM; Runyon, JP; Schneider, J; Shimshak, T; Whang, D | 1 |
| Adgey, AA; Mathew, TP | 1 |
| Dunn, A | 1 |
| Harrington, RA | 1 |
| Juran, NB | 1 |
| Dyke, CM | 1 |
| Chase, SL | 1 |
| Bhatia, D; Dyke, C | 1 |
| Akkerhuis, KM; Boersma, E; Califf, RM; Simoons, ML; Théroux, P; Topol, EJ | 1 |
| Bell, DM | 1 |
| Abbottsmith, CA; Anderson, LC; Blanck, C; Broderick, TM; Howard, W; Kereiakes, DJ; Lacock, P; Mueller, M; Roth, EM; Schneider, J; Whang, D | 1 |
| Abbottsmith, CW; Broderick, T; Howard, WL; Kereiakes, DJ; Martin, LH; McDonald, M; Roth, EM; Schneider, J; Shimshak, T; Whang, DD | 1 |
| Lincoff, AM; Roe, MT; Sapp, SK | 1 |
| Galli, M; Maggioni, AP; Tavazzi, L; Vassanelli, C | 1 |
| Cohen, M | 1 |
| Califf, RM; Lincoff, AM; Topol, EJ | 1 |
| Ikeda, Y | 1 |
| Broderick, TM; Kereiakes, DJ; Runyon, JP; Shimshak, TM | 1 |
| Byrne, KH; Hanlon, SJ; MacCallum, EM | 1 |
| Ferguson, JJ | 2 |
| Blankenship, JC; Dasgupta, H; Demko, SL; Frey, CM; Menapace, FJ; Wood, GC | 1 |
| Ball, S; Becker, RC; Li, Y; Spencer, FA | 1 |
| Blankenship, JC; Frey, CM; Memon, MA; Menapace, FJ; Wood, GC | 1 |
| Jang, IK; Sabatine, MS | 1 |
| Bozarth, JM; Forsythe, MS; Mousa, SA; Slee, A | 1 |
| Mak, KH; Moliterno, DJ | 1 |
| Holmes, DR | 1 |
| Bhatt, DL; Topol, EJ | 1 |
| Barnard, MR; Frelinger, AL; Furman, MI; Krueger, LA; Mascelli, MA; Michelson, AD; Nakada, MT | 1 |
| Blankenship, JC; Iliadis, EA | 1 |
| Braunwald, E; Califf, RM; Cannon, CP; Fox, KA; Fuster, V; Gibler, WB; Harrington, RA; King, SB; Kleiman, NS; Theroux, P; Topol, EJ; Van de Werf, F; White, HD; Willerson, JT | 1 |
| Shepard, RW | 1 |
| Agustí, A; Araujo, R | 1 |
| Montalescot, G | 1 |
| Hamm, C | 1 |
| Bachmann, LM; Golder, S; Kleijnen, J; McDonagh, MS; ter Riet, G | 1 |
| Berkowitz, SD | 1 |
| Kondo, K | 1 |
| Brown, DL; Chang, CJ; Fann, CS | 1 |
| Cannon, CP; Cohen, MC; Hochman, JS; Lucore, CL; O'Rourke, RA; Popma, JJ | 1 |
| Bassand, JP | 1 |
| Ganz, P; Kirshenbaum, JM; Liu, CB; Piana, RN; Popma, JJ; Rogers , C; Selwyn , AP; Simon, DI | 1 |
| Rodrigues, HL | 1 |
| Gawaz, M; Hochholzer, W; Neumann, FJ; Pogatsa-Murray, G; Schömig, A | 1 |
| Jordan, RE; Marciniak, SJ; Mascelli, MA | 1 |
| Hézard, N; Metz, D; Nguyên, P; Potron, G; Tassan-Mangina, S | 1 |
| Schrör, K | 1 |
| Willerson, JT; Wu, KK | 1 |
| Berger, PB; Braden, GA; Casterella, PJ; Dangas, G; Gallo, R; Holmes, DR; Jia, G; Kereiakes, DJ; Lincoff, AM; Moliterno, DJ; Navetta, FI; Popma, JJ; Sane, DC; Saucedo, JF; Steinhubl, SR; Talley, JD; Tcheng, JE; Teirstein, PS; Theroux, P | 1 |
| Nurden, P | 1 |
| Proimos, G | 1 |
| Vernon, SM | 1 |
| Stone, GW | 1 |
| Kurz, HI; Lasala, JM; Taniuchi, M | 1 |
| Lele, M; Sajid, M; Stouffer, GA; Wajih, N | 1 |
| Becker, RC; Li, YF; Spencer, FA | 2 |
| Schrör, K; Weber, AA | 1 |
| Becker, RC; Denier, D; Gouveia, W; Kimmelstiel, C; MacIsaac, DA; Miele, R; Phang, R; Rand, W; Rehman, A; Rhofiry, J | 1 |
| Lorenz, TJ; O'Shea, JC; Strony, J; Tcheng, JE | 1 |
| Badimon, JJ; Delfin, JA; Jayasundera, T; Lev, EI; Marmur, JD; Osende, JI; Richard, MF; Robbins, JA; Rodriguez, O; Sharma, SK | 1 |
| Boden, WE; McKay, RG | 1 |
| Cannizzaro, S; Di Pasquale, P; Giambanco, F; Giubilato, A; Paterna, S; Sarullo, FM; Scalzo, S; Vitrano, MG | 1 |
| Kini, AS; Mitre, CA; Reich, D; Sharma, SK | 1 |
| Kereiakes, DJ; Kukielka, G; Lorenz, T; Mueller, MN; Nanniazzi-Alaimo, L; Phillips, DR; Young, JJ | 1 |
| Fröhlich, E; Möckel, M; Störk, T | 1 |
| Galli, M | 1 |
| Chew, DP; Moliterno, DJ | 1 |
| SoRelle, R | 1 |
| Scarborough, RM | 1 |
| Sajid, M; Stouffer, GA | 1 |
| Johnson, K | 1 |
| Adamian, M; Collins, MB; Dangas, G; Iakovou, I; Kobayashi, Y; Lansky, AJ; Leon, MB; Mehran, R; Moses, JW; Polena, S; Roubin, GS; Stone, GW | 1 |
| Cercek, B; Finkelstein, A; Kaul, S; Rukshin, V; Shah, PK; Tsang, V | 1 |
| Leclerc, JR | 1 |
| Stevens, M | 1 |
| Jacoski, MV; Jennings, LK; White, MM | 1 |
| Kereiakes, DJ; Young, JJ | 2 |
| Bhatt, DL; Chew, DP | 1 |
| Jacobs, C; Kelm, M; Meila, D; Scharf, RE; Schrör, K; Strauer, BE; Weber, AA; Weber, S; Zotz, RB | 1 |
| Ahmad, S; Fareed, J; Hoppensteadt, DA; Ma, Q; Messmore, HL; Schultz, CL; Untch, B; Walenga, JM | 1 |
| Aster, RH; Bougie, DW; Curtis, BR; Levine, S; Lind, RN; Malik, M; Pereira, J; Wilker, PR; Wuitschick, ED | 1 |
| Fisher, EA; Kamran, M; Kini, AS; Lee, P; Marmur, JD; Perez, N; Richard, M; Sharma, SK; Suleman, J | 1 |
| Batchelor, WB; Califf, RM; Cantor, WJ; Davidian, M; DiBattiste, PM; Dillard, P; Gretler, D; Harrington, RA; Huang, Y; Larsen, RL; Mantell, RM; Ohman, EM; Sketch, MH; Tcheng, JE; Tolleson, TR; Zhang, D; Zidar, JP | 1 |
| Alpert, JS; Antman, EM; Beasley, JW; Braunwald, E; Califf, RM; Cheitlin, MD; Faxon, DP; Fuster, V; Gibbons, RJ; Gregoratos, G; Hiratzka, LF; Hochman, JS; Jacobs, AK; Jones, RH; Kereiakes, D; Kupersmith, J; Levin, TN; Pepine, CJ; Schaeffer, JW; Smith, EE; Smith, SC; Steward, DE; Theroux, P | 1 |
| Adelmeijer, J; De Groot, PG; Lisman, T; Moschatsis, S; Nieuwenhuis, HK | 1 |
| Barbera, FA; Dorsam, RT; Feuerstein, GZ; Friedman, SM; Gibbs, S; Lauver, A; Savion, N; Varon, D; Wang, H; Wang, X | 1 |
| Carrozza, JP; Cohen, DJ; Pinto, DS; Sperling, RT; Tu, TM | 1 |
| Christopoulos, CG | 1 |
| Ioannidis, JP; Karvouni, E; Katritsis, DG | 1 |
| Aguanno, JJ; Glover, EN; Schumacher, JR; Schussler, JM; Vish, NA; Wheelan, KR; Wissinger, LA | 1 |
| Ackman, M; Humphries, K; Jackevicius, C; Kertland, H; Shalansky, SJ; Tsuyuki, R; Virk, R | 1 |
| Alves, VL; Nannizzi-Alaimo, L; Phillips, DR | 1 |
| Tsakiris, DA | 1 |
| Jordan, RE; Kereiakes, DJ; Nakada, MT; Nedelman, MA; Sassoli, PM; Tam, SH | 1 |
| Bertram, U; Bode, C; Moser, M; Peter, K; Ruef, J | 1 |
| Hobbach, HP; Schuster, P | 1 |
| Ali, A; Gardin, JM; Hashem, M; Kazmouz, G; Rosman, HS; Schrieber, TL | 1 |
| Goldschmidt-Clermont, PJ; Kandzari, DE; Mayes, CE; Phillips, HR | 1 |
| Brown, DL; Green, SJ; Kaplan, RC; Ravi, KL; Sanborn, TA; Sherman, W; Slater, JN; Vakili, BA | 1 |
| Brown, DL | 1 |
| Goto, S | 1 |
| Bailey, S; Eles, G; Jarmolowski, C; Tan, WA; Toursakissian, B; Wholey, MH | 1 |
| Qureshi, AI | 1 |
| Foster, DA; McCollam, PL; Riesmeyer, JS | 1 |
| Heitzer, T; Köke, K; Meinertz, T; Munzel, T; Ollmann, I | 1 |
| Steinhubl, SR | 1 |
| Boersma, E; Westerhout, CM | 2 |
| Blazicek, H; Domanovits, H; Galehr, E; Jilma, B; Jilma-Stohlawetz, P; Mayr, F; Reiter, RA | 1 |
| Auer, J; Berent, R; Eber, B; Lassnig, E; Maurer, E; Weber, T | 1 |
| Goto, S; Handa, M; Handa, S; Ikeda, Y; Li, M; Ruggeri, ZM; Tamura, N | 1 |
| Antman, EM; Bates, ER; Cohen, M; Every, NR; Ferguson, JJ; Harrington, RA; Pepine, CJ; Theroux, P | 1 |
| Barnard, MR; Dae, MW; Frelinger, AL; Furman, MI; Krueger, LA; Michelson, AD | 1 |
| Boden, WE; Cannon, CP; Januzzi, JL; Theroux, P | 1 |
| Cochran, K; DeMartini, TJ; Grassman, ED; Lewis, BE; Leya, F; O Brien, J; Steen, LH | 1 |
| Merlini, PA; Rossi, ML | 1 |
| Derhaschnig, U; Jilma, B; Marsik, C; Pachinger, C; Schweeger-Exeli, I | 1 |
| Harrington, RA; Nguyen, CM | 1 |
| Atar, S; Birnbaum, Y; Chen, M; Kobal, S; Luo, H; Miyamoto, T; Neuman, Y; Siegel, RJ | 1 |
| Abrams, CS; Cines, DB | 1 |
| Bolton, ED; Braunstein, JB; Chiles, KA; Faraday, N; Gerstenblith, G; Heldman, AW; Schulman, SP | 1 |
| Haerten, K; Krabbe, C; Raiber, M | 1 |
| Corominas, N; Ferrer, E; Ortiz, J; Perez, J; Ribas, J; Sanz, G | 1 |
| Derhaschnig, U; Jilma, B; Pachinger, C | 1 |
| Dale, GL; Hamilton, SF; Miller, MW; Thompson, CA | 1 |
| Cook, SL; Garza, L; Jacoski, MV; Jennings, LK; Matin, Z; McGrew, FA; Ramanathan, KB; Saucedo, JF; Wolford, DC | 1 |
| Day, JR; Haskard, DO; Landis, RC; Malik, IS; Nadra, I; Poullis, M; Taylor, KM; Weerasinghe, A | 1 |
| Goto, S; Ishida, H; Tamura, N | 1 |
| Domanovits, H; Frossard, M; Fuchs, I; Hsieh, K; Jilma, B; Laggner, AN; Leitner, JM; Losert, H; Schreiber, W; Vlcek, M | 1 |
| Brouse, SD; Wiesehan, VG | 1 |
| Aster, RH; Bougie, DW; Curtis, BR | 1 |
| Gandhi, PJ; Silva, MA | 1 |
| Albuquerque, FC; Deshmukh, VR; Fiorella, DJ; Flaster, M; Frey, J; McDougall, CG; Spetzler, RF; Wallace, RC | 1 |
| Atwater, BD; Mahaffey, KW; Roe, MT | 1 |
| Aster, RH | 1 |
| Califf, RM; Crater, SW; Giugliano, RP; Green, CL; Harrington, RA; Johanson, P; Krucoff, MW; Langer, A; Lincoff, AM; Newby, LK; Rebeiz, AG; Roe, MT; Topol, EJ; Wagner, GS | 1 |
| Bailey, LA; Sistino, JJ; Uber, WE | 1 |
| Bao, M; Clauser, K; Conley, PB; Hart, MJ; Komuves, L; Lin, H; Nanda, N; Phillips, DR; Quertermous, T | 1 |
| Ilveskero, S; Lassila, R | 1 |
| Cohen, EA; Fort, S; Godin-Edgecombe, M; Madan, M; Naqvi, SZ; Paradiso-Hardy, FL; Phillips, AM; Radhakrishnan, S; Reis, M; Shanmugasegaram, S; Sparling, C | 1 |
| Baumann, PQ; Schneider, DJ; Sobel, BE; Whitaker, DA | 1 |
| Hursting, MJ; Patel, K | 1 |
| Le Pen, C; Lilliu, H | 1 |
| Aronson, D; Beyar, R; Boulos, M; Grenadier, E; Gruberg, L; Hammerman, H; Kapeliovich, M; Lavi, S; Markiewicz, W | 1 |
| Young, JJ | 1 |
| Chang, M; Dangas, G; Ellis, SG; Kao, J; Laufer, N; Mehran, R; Russell, ME; Stone, GW; Tannenbaum, MA; Teirstein, PS; Watkins, M | 1 |
| Bucha, E; Nowak, G; Schumann, A | 1 |
| Bhatt, DL; Duffy, B | 1 |
| Huxtable, LM; Rakkar, AN; Tafreshi, MJ | 1 |
| Glaser, R; Glick, HA; Herrmann, HC; Kimmel, SE | 1 |
| Ben-Yehuda, O | 1 |
| Aster, RH; Bougie, DW; Chong, BH; Curtis, BR; Dunkley, S; Greinacher, A; Warkentin, TE | 1 |
| Capuano, C; Danzi, GB; Mauri, L; Sesana, M; Sozzi, FB | 1 |
| Kecskés, M; Losonczy, H; Nagy, A; Pótó, L; Szabó, C; Tóth, O | 1 |
| Azevedo, R; Beierlein, W; Dietz, K; Straub, A; Wendel, HP; Ziemer, G | 1 |
| Ahrens, I; Bassler, N; Bode, C; Chen, YC; Fitzgerald, D; Hagemeyer, CE; Kenny, D; Meade, G; Moran, N; Peter, K; Schwarz, M; Stoll, P; Ylanne, J | 1 |
| Aguiar, C; Almeida, M; de Araujo Goncalves, P; Ferreira, J; Pereira Machado, F; Raposo, L; Seabra-Gomes, R; Teles, R | 1 |
| Jennings, LK | 1 |
| Alexander, KP; Chen, AY; Gibler, WB; Hochman, JS; Newby, LK; Ohman, EM; Peterson, ED; Redberg, RF; Roe, MT; Schwartz, JB | 1 |
| Radke, PW; Schunkert, H | 1 |
| Beer, JH; Deckmyn, H; Forestier, M; Pontiggia, L; Steiner, B; Ulrichts, H | 1 |
| Connor, JH; Connor, RF; Hantgan, RR; Mousa, SA; Stahle, MC | 1 |
| Ligon, RW; Markwell, SJ; Mishkel, GJ; Moore, AL | 1 |
| Fontana, P | 1 |
| Balbarini, A; Ciabatti, N; Cortese, B; De Carlo, M; De Caterina, R; Gistri, R; Levantino, M; Maselli, D; Petronio, AS | 1 |
| Cannon, CP; Chen, AY; Gibler, WB; Gibson, CM; Greenbaum, AB; Harrington, RA; Hoekstra, JW; Newby, LK; Ohman, EM; Peterson, ED; Pollack, CV; Roe, MT; Tricoci, P | 1 |
| Hauptmann, KE; Hochadel, M; Ischinger, T; Janicke, I; Jung, J; Mark, B; Mudra, H; Schramm, A; Seggewiss, H; Senges, J; Zahn, R; Zeymer, U | 1 |
| Arora, R; Deo, D; Deshpande, NV; Hiremath, JS; Hiremath, MS; Joseph, J; Khan, A; Mardikar, HM; Mathew, R; Moliterno, DJ; Mukherjee, D | 1 |
| Choi, M; Kettritz, R; Luft, FC; Rolle, S; Salanova, B; Wellner, M | 1 |
| Banerjee, S; Chen, S; Ho, C; Labinaz, M; Martin, J; Mensinkai, S | 1 |
| Agarwal, A; Cavusoglu, E; Manjappa, N; Marmur, JD; Poludasu, S | 1 |
| Boden, WE; Hoekstra, J; Miller, CD | 1 |
| Anderson, JL; Bair, TL; Burke, JL; Casterella, PJ; Horne, B; May, HT; Muhlestein, JB; Pearson, RR; Revenaugh, JR | 1 |
| Kent, TA; Mandava, P; Thiagarajan, P | 1 |
| Basani, RB; Bennett, JS; Degrado, WF; Kowalska, MA; Poncz, M; Soto, CS; Thornton, MA; Zhu, H | 1 |
| Cavusoglu, E; Lazar, J; Marmur, JD; Poludasu, S | 1 |
| Zijlstra, F | 1 |
| Cassetti, E; De Luca, G; Marino, P; Ucci, G | 1 |
| Brener, SJ | 1 |
| Hantgan, RR; Stahle, MC | 1 |
| Eriksson, AC; Whiss, PA | 1 |
| De Luca, G; Marino, P; Navarese, E | 1 |
| Allen, DJ; Freedman, J; Gyulkhandanyan, AV; Leytin, V; Mutlu, A; Mykhaylov, S | 1 |
| Bates, ER; Chetcuti, S; Grossman, PM; Gurm, HS; Meier, P; Tamhane, U | 1 |
| Dong, L; Shu, X; Zhang, F | 1 |
| Armstrong, PW; Aylward, PE; Betriu, GA; Granger, CB; Holmes, DR; Huber, K; Montalescot, G; van 't Hof, AW; Westerhout, CM; Widimsky, P | 1 |
| Catapano, O; De Vita, M; Galvani, M; La Vecchia, L; Ottani, F; Tarantino, F | 1 |
| Cuturello, D; Missiroli, B; Puddu, PE; Saladini, A; Schiariti, M | 1 |
| Biondi-Zoccai, G; Lioy, E; Rasoul, S; Romagnoli, E; Sciahbasi, A; Stone, GW; Valgimigli, M; van't Hof, A | 1 |
| Bongo, AS; Cavallino, C; Lazzero, M; Lupi, A; Rognoni, A; Sansa, M; Secco, GG | 1 |
| Armstrong, PW; Bolognese, L; Braunwald, E; Califf, RM; Durand, E; Giugliano, RP; Harrington, RA; Hasselblad, V; Kong, DF; Moliterno, DJ; Newby, LK; Prabhakaran, D; Rasoul, S; Stone, GW; Théroux, P; Tricoci, P; Van de Werf, F; White, HD | 1 |
| Schneider, DJ | 1 |
| Eisenberg, MJ; Friedland, S; Shimony, A | 1 |
| De Caterina, R; Grove, EL; Huber, K; Kristensen, SD; Moliterno, DJ; Neumann, FJ; Würtz, M | 1 |
| Allen, A; Armstrong, N; Di Nisio, M; Kleijnen, J; Lang, SH; Manning, N; Misso, K | 1 |
| Baroni, M; Musumeci, G; Rossini, R | 1 |
| Aster, RH; Bougie, DW; Rasmussen, M; Zhu, J | 1 |
| Bellandi, F; Cutlip, D; De Luca, G; Dudek, D; Emre, A; Gabriel, HM; Gibson, CM; Gyongyosi, M; Huber, K; Maioli, M; Noc, M; Rakowski, T; Secco, GG; van 't Hof, AW; Zeymer, U; Zorman, S | 1 |
| Bennett, JS; Hook, KM | 1 |
| Bellomo, G; Camaro, C; De Luca, G; Di Giovine, G; Marino, P; Pergolini, P; Restifo, M; Rolla, R; Schaffer, A; Suryapranata, H; Verdoia, M | 1 |
| Fedyanin, AA; Gafarova, MA; Khokhlova, MD; Kryukova, DV; Lyubin, EV; Muravyov, AV; Rikova, SY; Shahnazarov, AA; Skryabina, MN; Sokolova, IA | 1 |
| Fahy, M; Kirtane, AJ; Lee, EA; Mehran, R; Nazif, TM; Parise, H; Stone, GW | 1 |
| Angiolillo, DJ; Antonelli, M; Biglioli, F; Boni, L; Bovenzi, F; Bozzani, A; Bramucci, E; Buffoli, F; Capodanno, D; Castiglioni, B; Comel, A; Cremonesi, A; Crescini, C; D'Angelo, F; De Servi, S; Dionigi, G; Droghetti, A; Francetti, L; Gadda, F; Guagliumi, G; Lettieri, C; Lettino, M; Lorini, L; Musumeci, G; Parolari, A; Piccaluga, E; Ravelli, P; Rossini, R; Salvi, L; Savonitto, S; Scarone, P; Setacci, C; Staurenghi, G; Trabattoni, D; Valdatta, L; Visconti, LO | 1 |
| Brinjikji, W; Cloft, HJ; Kallmes, DF; Morales-Valero, SF; Murad, MH | 1 |
| Anderson, JL; Bates, ER; Bode, C; Granger, CB; Huber, K; Kristensen, SD; Lopez Sendon, JL; Ohman, EM; Steg, PG; Tubaro, M; Valgimigli, M; Wallentin, L | 1 |
| Harmon, C; King, S; Short, M | 1 |
| He, Y; Jin, J; Li, J; Qian, D; Yu, S | 1 |
| Coscioni, E; D'Angelillo, A; Giordano, A; Messina, S; Musumeci, G; Romano, MF; Romano, S; Rossini, R; Zoccai, GB | 1 |
| Avakian, SD; Caribé, PM; Mansur, Ade P; Roggerio, A; Strunz, CM; Takada, JY | 1 |
| Bansilal, S; Becker, RC; Cannon, CP; Harrington, RA; Himmelmann, A; Husted, S; James, SK; Katus, HA; Lopes, RD; Neely, B; Shimada, YJ; Steg, PG; Storey, RF; Wallentin, L; Wiviott, SD | 1 |
| French, JK; Gupta, R; Holmes, LE; Juergens, CP; Luu, J; Rajendran, S | 1 |
| Cao, Y; Ding, X; Gamariel, RR; Kong, Y; Li, ZY; Liu, TD; Liu, XD; Ming, X; Wang, CH; Xie, ZL; Zhao, Q | 1 |
| Li, J; Sun, H; Wu, X; Zhou, X | 1 |
| Chang, J; Han, B; Luo, Y; Ma, K; Mao, M; Wu, F; Xiang, R; Zuo, Z | 1 |
| Cheung, HYF; Garcia, Á; Heemskerk, JWM; Moran, LA; Sickmann, A; Watson, SP | 1 |
107 review(s) available for tyrosine and eptifibatide
| Article | Year |
|---|---|
Glycoprotein IIb/IIIa receptor inhibitors: putting the EPIC, IMPACT II, RESTORE, and EPILOG trials into perspective.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Atherectomy, Coronary; Constriction, Pathologic; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Randomized Controlled Trials as Topic; Recurrence; Stents; Tirofiban; Treatment Outcome; Tyrosine | 1996 |
The anti-GPIIb-IIIa agents: fundamental and clinical aspects.
Topics: Abciximab; Angina, Unstable; Angioplasty, Balloon, Coronary; Animals; Antibodies, Monoclonal; Clinical Trials as Topic; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Drug Evaluation, Preclinical; Eptifibatide; Hemorrhage; Humans; Immunoglobulin Fab Fragments; Mice; Multicenter Studies as Topic; Oligopeptides; Peptides; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Recombinant Fusion Proteins; Thrombosis; Tirofiban; Tyrosine | 1996 |
[Platelet membrane glycoproteins as site of pharmacological intervention in the treatment of coronary disease].
Topics: Abciximab; Acetates; Alkynes; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Benzamidines; Binding Sites; Clinical Trials as Topic; Clinical Trials, Phase III as Topic; Coronary Disease; Double-Blind Method; Eptifibatide; Fibrinolytic Agents; Humans; Immunoglobulin Fab Fragments; Myocardial Infarction; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIb-IX Complex; Platelet Membrane Glycoproteins; Randomized Controlled Trials as Topic; Receptors, Antigen, B-Cell; Receptors, Cell Surface; Time Factors; Tirofiban; Tyrosine | 1997 |
Glycoprotein IIb/IIIa receptor antagonists for the treatment of unstable angina.
Topics: Abciximab; Acetates; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clinical Trials as Topic; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Myocardial Ischemia; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Recurrence; Tirofiban; Treatment Outcome; Tyrosine | 1997 |
An overview of the results of clinical trials with glycoprotein IIb/IIIa inhibitors.
Topics: Abciximab; Acetates; Antibodies, Monoclonal; Blood Platelets; Clinical Trials as Topic; Coronary Disease; Cost-Benefit Analysis; Dose-Response Relationship, Drug; Eptifibatide; Follow-Up Studies; Humans; Immunoglobulin Fab Fragments; Infusions, Intravenous; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Syndrome; Tirofiban; Treatment Outcome; Tyrosine | 1998 |
New antiplatelet agents for acute coronary syndromes.
Topics: Abciximab; Acetates; Acute Disease; Antibodies, Monoclonal; Blood Platelets; Coronary Disease; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Injections, Intravenous; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Syndrome; Tirofiban; Tyrosine | 1998 |
An overview of the results of clinical trials with glycoprotein IIb/IIIa inhibitors.
Topics: Abciximab; Acetates; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Atherectomy, Coronary; Coronary Disease; Eptifibatide; Fibrinolytic Agents; Heparin; Humans; Immunoglobulin Fab Fragments; Myocardial Infarction; Myocardial Ischemia; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Randomized Controlled Trials as Topic; Survival Analysis; Thrombolytic Therapy; Tirofiban; Treatment Outcome; Tyrosine | 1998 |
Trials of platelet glycoprotein IIb/IIIa receptor antagonists during percutaneous coronary revascularization.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clinical Trials as Topic; Coronary Disease; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Research Design; Tirofiban; Treatment Outcome; Tyrosine | 1998 |
Glycoprotein IIb-IIIa antagonists in percutaneous coronary interventions and acute coronary syndromes.
Topics: Abciximab; Angina, Unstable; Angioplasty; Antibodies, Monoclonal; Coronary Artery Bypass; Coronary Disease; Eptifibatide; Female; Humans; Immunoglobulin Fab Fragments; Male; Myocardial Ischemia; Myocardial Revascularization; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Stents; Tirofiban; Tyrosine | 1998 |
Pharmacology of the intravenous platelet receptor glycoprotein IIb-IIIa antagonists.
Topics: Abciximab; Acetates; Antibodies, Monoclonal; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Peptides; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Thrombosis; Tirofiban; Tyrosine | 1998 |
Recent antiplatelet drug trials in the acute coronary syndromes. Clinical interpretation of PRISM, PRISM-PLUS, PARAGON A and PURSUIT.
Topics: Acetates; Acute Disease; Anticoagulants; Coronary Disease; Drug Therapy, Combination; Eptifibatide; Heparin; Humans; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Randomized Controlled Trials as Topic; Tirofiban; Tyrosine | 1998 |
Platelet glycoprotein IIb/IIIa inhibitor therapy in acute myocardial infarction.
Topics: Abciximab; Acetates; Antibodies, Monoclonal; Blood Coagulation; Clinical Trials as Topic; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Myocardial Infarction; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Safety; Treatment Outcome; Tyrosine | 1998 |
Use of glycoprotein IIb/IIIa inhibition plus fibrinolysis in acute myocardial infarction.
Topics: Abciximab; Acetates; Animals; Antibodies, Monoclonal; Clinical Trials as Topic; Clinical Trials, Phase II as Topic; Dogs; Double-Blind Method; Drug Evaluation, Preclinical; Drug Therapy, Combination; Eptifibatide; Fibrinogen; Fibrinolytic Agents; Forecasting; Humans; Immunoglobulin Fab Fragments; Myocardial Infarction; Peptides; Pilot Projects; Plasminogen Activators; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Randomized Controlled Trials as Topic; Recurrence; Treatment Outcome; Tyrosine | 1999 |
Glycoprotein IIb/IIIa receptor inhibition in interventional cardiology.
Topics: Abciximab; Administration, Oral; Adult; Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Cardiology; Clinical Trials as Topic; Coronary Disease; Double-Blind Method; Embolism; Eptifibatide; Female; Fibrinolytic Agents; Follow-Up Studies; Forecasting; Hemorrhage; Humans; Immunoglobulin Fab Fragments; Male; Meta-Analysis as Topic; Middle Aged; Multicenter Studies as Topic; Myocardial Infarction; Peptides; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prospective Studies; Risk; Stents; Structure-Activity Relationship; Tirofiban; Treatment Outcome; Tyrosine | 1999 |
Antiplatelet therapy for treatment of acute coronary syndromes.
Topics: Abciximab; Acetates; Antibodies, Monoclonal; Aspirin; Clopidogrel; Coronary Disease; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Peptides; Platelet Aggregation Inhibitors; Ticlopidine; Tirofiban; Treatment Outcome; Tyrosine; Vascular Patency | 1999 |
Platelet glycoprotein IIb/IIIa antagonists in percutaneous coronary revascularization.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clinical Trials as Topic; Coronary Thrombosis; Eptifibatide; Forecasting; Humans; Immunoglobulin Fab Fragments; Myocardial Infarction; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Stents; Tirofiban; Tyrosine | 1999 |
Economic issues in glycoprotein IIb/IIIa receptor therapy.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Coronary Disease; Drug Costs; Eptifibatide; Fibrinolytic Agents; Humans; Immunoglobulin Fab Fragments; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Stents; Tirofiban; Tyrosine | 1999 |
Use of glycoprotein IIb/IIIa inhibitors in patients with coronary artery disease.
Topics: Abciximab; Acetates; Acute Disease; Administration, Oral; Angina, Unstable; Antibodies, Monoclonal; Clinical Trials as Topic; Coronary Disease; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Infusions, Intravenous; Myocardial Infarction; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Tirofiban; Tyrosine | 1999 |
Clinical trials of IIb/IIIa receptor blockers in patients undergoing angioplasty.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Coronary Disease; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Randomized Controlled Trials as Topic; Safety; Tirofiban; Tyrosine | 1999 |
Overview of clinical trials of glycoprotein IIb-IIIa inhibitors in acute coronary syndromes.
Topics: Acute Disease; Anticoagulants; Aspirin; Clinical Trials as Topic; Coronary Disease; Coronary Thrombosis; Eptifibatide; Fibrinolytic Agents; Heparin; Humans; Myocardial Ischemia; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Tirofiban; Tyrosine | 1999 |
Minimizing bleeding complications of percutaneous coronary intervention and glycoprotein IIb-IIIa antiplatelet therapy.
Topics: Abciximab; Antibodies, Monoclonal; Anticoagulants; Aspirin; Catheterization, Peripheral; Coronary Disease; Coronary Thrombosis; Eptifibatide; Femoral Artery; Fibrinolytic Agents; Hemorrhage; Heparin; Humans; Immunoglobulin Fab Fragments; Myocardial Revascularization; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Tirofiban; Tyrosine | 1999 |
Safety of glycoprotein IIb-IIIa inhibitors: A heart surgeon's perspective.
Topics: Abciximab; Acute Disease; Antibodies, Monoclonal; Blood Platelets; Coronary Artery Bypass; Coronary Disease; Coronary Thrombosis; Eptifibatide; Fibrinolytic Agents; Hemorrhage; Humans; Immunoglobulin Fab Fragments; Incidence; Myocardial Ischemia; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Risk Factors; Safety; Tirofiban; Tyrosine | 1999 |
Inhibitors of the platelet receptor glycoprotein IIb-IIIa and complications during percutaneous coronary revascularization. Management strategies for the cardiac surgeon.
Topics: Cardiopulmonary Bypass; Coronary Artery Bypass; Coronary Thrombosis; Dose-Response Relationship, Drug; Emergencies; Eptifibatide; Hemostasis, Surgical; Humans; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Randomized Controlled Trials as Topic; Tirofiban; Tyrosine | 1999 |
Platelet glycoprotein IIb/IIIa receptor inhibition in non-ST-elevation acute coronary syndromes: early benefit during medical treatment only, with additional protection during percutaneous coronary intervention.
Topics: Abciximab; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Electrocardiography; Eptifibatide; Female; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Randomized Controlled Trials as Topic; Tirofiban; Tyrosine | 1999 |
Analysis of number needed to treat and cost of platelet glycoprotein IIb/IIIa inhibitors in percutaneous coronary interventions and acute coronary syndromes.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Coronary Disease; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Myocardial Infarction; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Randomized Controlled Trials as Topic; Retrospective Studies; Risk Factors; Tirofiban; Tyrosine; Vascular Surgical Procedures | 1999 |
Clinical challenges of platelet glycoprotein IIb/IIIa receptor inhibitor therapy: bleeding, reversal, thrombocytopenia, and retreatment.
Topics: Eptifibatide; Hemorrhage; Humans; Myocardial Ischemia; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Recurrence; Risk Factors; Survival Rate; Thrombocytopenia; Tirofiban; Tyrosine | 2000 |
Platelet glycoprotein IIb/IIIa receptor blockers: An appropriate-use model for expediting care in acute coronary syndromes.
Topics: Abciximab; Acute Disease; Antibodies, Monoclonal; Coronary Disease; Drug Therapy, Combination; Electrocardiography; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Tirofiban; Treatment Outcome; Tyrosine | 2000 |
Glycoprotein IIb/IIIa inhibitors in acute coronary syndromes.
Topics: Abciximab; Angina, Unstable; Antibodies, Monoclonal; Drug Therapy, Combination; Eptifibatide; Fibrinolytic Agents; Heparin; Humans; Immunoglobulin Fab Fragments; Myocardial Infarction; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Tirofiban; Tyrosine | 2000 |
[The clinical use of the GPIIb/IIIa inhibitors eptifibatide and tirofiban in the treatment of acute coronary syndromes of the "non-ST elevation" type].
Topics: Acute Disease; Clinical Trials as Topic; Coronary Disease; Electrocardiography; Eptifibatide; Humans; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Risk Factors; Syndrome; Tirofiban; Tyrosine | 2000 |
Treatment of unstable angina: the role of platelet inhibitors and anticoagulants.
Topics: Abciximab; Angina, Unstable; Antibodies, Monoclonal; Anticoagulants; Clopidogrel; Coronary Thrombosis; Endothelium, Vascular; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Ticlopidine; Tirofiban; Tyrosine | 1999 |
Platelet glycoprotein IIb/IIIa receptor blockade in coronary artery disease.
Topics: Abciximab; Acetates; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Combined Modality Therapy; Coronary Disease; Drug Monitoring; Eptifibatide; Hemorrhage; Humans; Immunoglobulin Fab Fragments; Infusions, Intravenous; Myocardial Infarction; Patient Selection; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Practice Guidelines as Topic; Recurrence; Risk Factors; Tirofiban; Treatment Outcome; Tyrosine | 2000 |
[GPIIb/IIIa inhibitor].
Topics: Abciximab; Antibodies, Monoclonal; Clinical Trials as Topic; Coronary Thrombosis; Drug Design; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Peptides; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Tirofiban; Tyrosine | 2000 |
Thrombocytopenia complicating treatment with intravenous glycoprotein IIb/IIIa receptor inhibitors: a pooled analysis.
Topics: Abciximab; Antibodies, Monoclonal; Eptifibatide; Hemorrhage; Humans; Immunoglobulin Fab Fragments; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Randomized Controlled Trials as Topic; Thrombocytopenia; Tirofiban; Tyrosine | 2000 |
Incidence of intracranial hemorrhage complicating treatment with glycoprotein IIb/IIIa receptor inhibitors: a pooled analysis of major clinical trials.
Topics: Abciximab; Acetates; Acute Disease; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Coronary Disease; Drug Therapy, Combination; Eptifibatide; Heparin; Humans; Immunoglobulin Fab Fragments; Incidence; Infusions, Intravenous; Intracranial Hemorrhages; Odds Ratio; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Randomized Controlled Trials as Topic; Syndrome; Tirofiban; Tyrosine | 2000 |
The use of glycoprotein IIb/IIIa inhibitors in patients with coronary artery disease.
Topics: Abciximab; Acetates; Acute Disease; Administration, Oral; Alanine; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Benzamidines; Coronary Disease; Eptifibatide; Hemorrhage; Humans; Immunoglobulin Fab Fragments; Myocardial Infarction; Oximes; Peptides; Piperidines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Pyrrolidines; Randomized Controlled Trials as Topic; Stents; Syndrome; Thrombocytopenia; Thrombolytic Therapy; Tirofiban; Tyrosine | 2000 |
Platelet glycoprotein IIb/IIIa inhibition in acute coronary syndromes.
Topics: Acetates; Acute Disease; Eptifibatide; Hemorrhage; Humans; Myocardial Infarction; Myocardial Ischemia; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Randomized Controlled Trials as Topic; Risk Factors; Survival Analysis; Tirofiban; Tyrosine | 1999 |
Platelet glycoprotein receptor site blockade in coronary artery disease.
Topics: Abciximab; Angina, Unstable; Antibodies, Monoclonal; Coronary Disease; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Myocardial Infarction; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Randomized Controlled Trials as Topic; Stents; Syndrome; Tirofiban; Treatment Outcome; Tyrosine | 2000 |
Current role of platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes.
Topics: Abciximab; Acute Disease; Alanine; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Benzamidines; Drug Therapy, Combination; Eptifibatide; Heparin, Low-Molecular-Weight; Humans; Immunoglobulin Fab Fragments; Myocardial Infarction; Oximes; Peptides; Piperidines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Pyrrolidines; Randomized Controlled Trials as Topic; Stents; Tirofiban; Tyrosine | 2000 |
Redefining medical treatment in the management of unstable angina.
Topics: Abciximab; Administration, Oral; Angina, Unstable; Antibodies, Monoclonal; C-Reactive Protein; Diagnosis, Differential; Enoxaparin; Eptifibatide; Government Agencies; Heparin, Low-Molecular-Weight; Humans; Immunoglobulin Fab Fragments; Infusions, Intravenous; Myocardial Infarction; National Institutes of Health (U.S.); Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Practice Guidelines as Topic; Risk; Time Factors; Tirofiban; Troponin I; Troponin T; Tyrosine; United States | 2000 |
Pharmacology: antiplatelet and antithrombin therapy in acute coronary syndromes.
Topics: Abciximab; Antibodies, Monoclonal; Antithrombins; Coronary Disease; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Peptides; Platelet Aggregation Inhibitors; Tirofiban; Tyrosine | 2000 |
Value of antiplatelet therapy in preventing thrombotic events in generalized vascular disease.
Topics: Arteriosclerosis; Clopidogrel; Eptifibatide; Humans; Myocardial Infarction; Peptides; Platelet Aggregation Inhibitors; Stroke; Ticlopidine; Tirofiban; Tyrosine | 2000 |
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of glycoprotein IIb/IIIa antagonists in the medical management of unstable angina.
Topics: Acetates; Angina, Unstable; Biphenyl Compounds; Cost-Benefit Analysis; Eptifibatide; Female; Humans; Male; Oximes; Peptides; Piperidines; Platelet Aggregation Inhibitors; Pyrrolidines; Tirofiban; Tyrosine | 2000 |
Current knowledge of the platelet glycoprotein IIb/IIIa receptor antagonists for the treatment of coronary artery disease.
Topics: Abciximab; Acetates; Angina, Unstable; Angioplasty, Balloon, Coronary; Animals; Antibodies, Monoclonal; Coronary Artery Bypass; Coronary Disease; Drug Approval; Eptifibatide; Hemorrhage; Humans; Immunoglobulin Fab Fragments; Mice; Multicenter Studies as Topic; Myocardial Ischemia; Peptides; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Randomized Controlled Trials as Topic; Recombinant Fusion Proteins; Recurrence; Safety; Single-Blind Method; Stents; Survival Analysis; Tirofiban; Treatment Outcome; Tyrosine; United States; United States Food and Drug Administration | 2000 |
[Investigational new drugs among glycoprotein IIb/IIIa-receptor antagonists].
Topics: Abciximab; Antibodies, Monoclonal; Clinical Trials as Topic; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Myocardial Ischemia; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Tirofiban; Tyrosine | 2000 |
Meta-analysis of effectiveness and safety of abciximab versus eptifibatide or tirofiban in percutaneous coronary intervention.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Combined Modality Therapy; Coronary Disease; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Peptides; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Survival Rate; Tirofiban; Treatment Outcome; Tyrosine | 2001 |
New approaches to diagnosis and management of unstable angina and non-ST-segment elevation myocardial infarction.
Topics: Algorithms; Angina, Unstable; Antithrombins; Biomarkers; Diagnosis, Differential; Electrocardiography; Eptifibatide; Heparin, Low-Molecular-Weight; Humans; Myocardial Infarction; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Risk Factors; Tirofiban; Tyrosine | 2001 |
Low-molecular-weight heparin and other antithrombotic agents in the setting of a fast-track revascularization in unstable coronary artery disease.
Topics: Abciximab; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Aspirin; Clinical Trials as Topic; Combined Modality Therapy; Diabetes Complications; Drug Therapy, Combination; Eptifibatide; Factor Xa Inhibitors; Heparin, Low-Molecular-Weight; Hirudin Therapy; Hirudins; Humans; Immunoglobulin Fab Fragments; Myocardial Revascularization; Oligosaccharides; Peptide Fragments; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Postoperative Complications; Randomized Controlled Trials as Topic; Recombinant Proteins; Risk Factors; Thrombocytopenia; Thrombosis; Time Factors; Tirofiban; Treatment Outcome; Tyrosine | 2000 |
[Update on the treatment with platelet antiaggregation agents].
Topics: Abciximab; Adenosine Diphosphate; Antibodies, Monoclonal; Arachidonic Acid; Cell Membrane; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Peptides; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prostaglandin-Endoperoxide Synthases; Thromboxane A2; Tirofiban; Tyrosine | 2001 |
[GPIIb-IIIa inhibitors].
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Coronary Disease; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Myocardial Infarction; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Tirofiban; Tyrosine | 2001 |
Platelet aggregation inhibition with glycoprotein IIb--IIIa inhibitors.
Topics: Abciximab; Adenosine Diphosphate; Amino Acid Chloromethyl Ketones; Antibodies, Monoclonal; Anticoagulants; Clinical Trials as Topic; Coronary Disease; Dose-Response Relationship, Drug; Drug Interactions; Eptifibatide; Heparin; Humans; Immunoglobulin Fab Fragments; Oligopeptides; Peptides; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Platelet Glycoprotein GPIIb-IIIa Complex; Proteins; Receptors, Thrombin; Thrombin; Tirofiban; Tyrosine | 2001 |
Glycoprotein IIb/IIIa antagonists and low-molecular weight heparin in acute coronary syndromes.
Topics: Abciximab; Angina, Unstable; Antibodies, Monoclonal; Coronary Artery Bypass; Dalteparin; Enoxaparin; Eptifibatide; Fibrinolytic Agents; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Immunoglobulin Fab Fragments; Myocardial Infarction; Nadroparin; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Thrombocytopenia; Thrombosis; Tirofiban; Transaminases; Tyrosine | 2001 |
ESPRIT in context: pharmacology matters!
Topics: Abciximab; Angioplasty; Antibodies, Monoclonal; Eptifibatide; Half-Life; Humans; Immunoglobulin Fab Fragments; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Tirofiban; Tyrosine | 2001 |
Small peptide GP IIb/IIIa receptor inhibitors as upstream therapy in non-ST-segment elevation acute coronary syndromes: results of the PURSUIT, PRISM, PRISM-PLUS, TACTICS, and PARAGON trials.
Topics: Acetates; Clinical Trials as Topic; Electrocardiography; Eptifibatide; Heart Conduction System; Humans; Myocardial Infarction; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Risk Factors; Time Factors; Tirofiban; Treatment Outcome; Tyrosine | 2001 |
GP IIb/IIIa inhibitors in coronary artery disease management: what the latest trials tell us.
Topics: Abciximab; Acute Disease; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Atherectomy; Clinical Trials as Topic; Coronary Disease; Eptifibatide; Fibrinolytic Agents; Humans; Immunoglobulin Fab Fragments; Myocardial Infarction; Peptides; Placebos; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Stents; Syndrome; Time Factors; Tirofiban; Treatment Outcome; Troponin T; Tyrosine | 2001 |
The role of alpha(v)beta3 integrins in vascular healing.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Apoptosis; Cell Adhesion; Chemotaxis, Leukocyte; Clinical Trials as Topic; Coronary Restenosis; Coronary Stenosis; Drug Evaluation, Preclinical; Endothelium, Vascular; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Models, Animal; Papio; Peptides; Platelet Adhesiveness; Rabbits; Rats; Receptors, Vitronectin; Signal Transduction; Swine; Tirofiban; Tyrosine; Vasculitis; Wound Healing | 2002 |
Platelet glycoprotein IIb/IIIa antagonists: lessons learned from clinical trials and future directions.
Topics: Abciximab; Antibodies, Monoclonal; Clinical Trials as Topic; Coronary Disease; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Integrins; Peptides; Platelet Aggregation; Platelet Glycoprotein GPIIb-IIIa Complex; Tirofiban; Tyrosine | 2002 |
The pharmacodynamics of parenteral glycoprotein IIb/IIIa inhibitors.
Topics: Abciximab; Antibodies, Monoclonal; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Peptides; Platelet Glycoprotein GPIIb-IIIa Complex; Tirofiban; Tyrosine | 2002 |
Platelet glycoprotein IIb/IIIa inhibitor use during percutaneous coronary intervention: IIb or Not IIb, what is the question?
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Combined Modality Therapy; Eptifibatide; Female; Humans; Immunoglobulin Fab Fragments; Intraoperative Care; Male; Myocardial Infarction; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Randomized Controlled Trials as Topic; Sensitivity and Specificity; Tirofiban; Treatment Outcome; Tyrosine | 2002 |
Optimizing glycoprotein IIb/IIIa inhibition: lessons from recent randomized controlled trials.
Topics: Abciximab; Acute Disease; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Dose-Response Relationship, Drug; Drug Administration Schedule; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Myocardial Infarction; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Syndrome; Time Factors; Tirofiban; Treatment Outcome; Tyrosine | 2002 |
Combination platelet glycoprotein IIb/IIIa receptor and lepirudin administration during percutaneous coronary intervention in patients with heparin-induced thrombocytopenia.
Topics: Abciximab; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Drug Therapy, Combination; Eptifibatide; Female; Fibrinolytic Agents; Heparin; Hirudins; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Recombinant Proteins; Thrombocytopenia; Tirofiban; Tyrosine | 2003 |
Intravenous glycoprotein IIb/IIIa receptor antagonists reduce mortality after percutaneous coronary interventions.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Atherectomy, Coronary; Coronary Disease; Eptifibatide; Female; Humans; Immunoglobulin Fab Fragments; Infusions, Intravenous; Male; Middle Aged; Multicenter Studies as Topic; Myocardial Infarction; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Postoperative Hemorrhage; Randomized Controlled Trials as Topic; Risk; Stents; Survival Analysis; Tirofiban; Tyrosine | 2003 |
Pharmacodynamic and clinical trials of glycoprotein IIb/IIIa inhibitors and potential relationship of results to dosing.
Topics: Abciximab; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Clinical Trials as Topic; Eptifibatide; Fibrinolytic Agents; Forecasting; Humans; Immunoglobulin Fab Fragments; Infusions, Parenteral; Myocardial Infarction; Peptides; Placebos; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Risk Factors; Time Factors; Tirofiban; Tyrosine | 2003 |
The complementary use of glycoprotein IIb/IIIa inhibitors and drug-eluting stents in contemporary percutaneous coronary intervention.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Myocardial Ischemia; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Practice Guidelines as Topic; Stents; Tirofiban; Tyrosine | 2002 |
[GP IIb/IIIa receptor prevention medicine].
Topics: Abciximab; Animals; Antibodies, Monoclonal; Aspirin; Clinical Trials as Topic; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Myocardial Infarction; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Thrombolytic Therapy; Tirofiban; Tyrosine | 2003 |
Assessing platelet function during treatment with glycoprotein IIb/IIIa antagonists.
Topics: Acetates; Animals; Blood Coagulation; Blood Platelets; Eptifibatide; Humans; Peptides; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Tyrosine | 2003 |
Risk-benefit analysis of platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes.
Topics: Abciximab; Acetates; Acute Disease; Antibodies, Monoclonal; Coronary Disease; Drug Evaluation; Eptifibatide; Guidelines as Topic; Humans; Immunoglobulin Fab Fragments; Incidence; Injections, Intravenous; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Risk Assessment; Tirofiban; Treatment Outcome; Tyrosine | 2003 |
[Platelet glycoprotein IIb/IIIa inhibitors in coronary artery disease].
Topics: Abciximab; Administration, Oral; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Controlled Clinical Trials as Topic; Coronary Artery Bypass; Coronary Disease; Drug Therapy, Combination; Electrocardiography; Emergencies; Eptifibatide; Follow-Up Studies; Humans; Immunoglobulin Fab Fragments; Myocardial Infarction; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Randomized Controlled Trials as Topic; Risk Factors; Stents; Syndrome; Thrombocytopenia; Thrombolytic Therapy; Time Factors; Tirofiban; Tyrosine | 2003 |
Optimizing glycoprotein IIb/IIIa receptor antagonist use for the non-ST-segment elevation acute coronary syndromes: risk stratification and therapeutic intervention.
Topics: Abciximab; Acute Disease; Aged; Antibodies, Monoclonal; Coronary Disease; Eptifibatide; Female; Humans; Immunoglobulin Fab Fragments; Male; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Risk Assessment; Syndrome; Tirofiban; Tyrosine | 2003 |
[Role of GP IIb/IIIa blockers in clinical cardiology].
Topics: Abciximab; Angina, Unstable; Antibodies, Monoclonal; Coronary Disease; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Myocardial Infarction; Peptides; Platelet Glycoprotein GPIIb-IIIa Complex; Tirofiban; Tyrosine | 2003 |
Glycoprotein IIb/IIIa receptor antagonists: a comparative review of their use in percutaneous coronary intervention.
Topics: Abciximab; Angioplasty; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Coronary Restenosis; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Myocardial Infarction; Peptides; Platelet Glycoprotein GPIIb-IIIa Complex; Randomized Controlled Trials as Topic; Thrombosis; Tirofiban; Tyrosine | 2003 |
Thrombocytopenia after treatment with platelet glycoprotein IIb/IIIa inhibitors.
Topics: Abciximab; Animals; Antibodies, Monoclonal; Antibody Specificity; Clinical Trials as Topic; Epitopes; Eptifibatide; Fibrinogen; Humans; Immunoglobulin Fab Fragments; Mice; Myocardial Infarction; Peptides; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Recombinant Fusion Proteins; Thrombocytopenia; Tirofiban; Tyrosine | 2004 |
Intravenous glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: lessons from recently conducted randomized clinical trials.
Topics: Abciximab; Acetates; Acute Disease; Antibodies, Monoclonal; Coronary Disease; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Injections, Intravenous; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Randomized Controlled Trials as Topic; Tirofiban; Tyrosine | 2004 |
Thrombocytopenia resulting from sensitivity to GPIIb-IIIa inhibitors.
Topics: Abciximab; Antibodies, Monoclonal; Diagnosis, Differential; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Immunoglobulin G; Ligands; Models, Chemical; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Risk Factors; Thrombocytopenia; Tirofiban; Tyrosine | 2004 |
Selection of glycoprotein IIb/IIIa inhibitors for upstream use in patients with diabetes experiencing unstable angina or non-ST segment elevation myocardial infarction. What have we learned in the last 10 years?
Topics: Abciximab; Angina, Unstable; Antibodies, Monoclonal; Clinical Trials as Topic; Diabetes Complications; Diabetes Mellitus; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Myocardial Infarction; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Tirofiban; Tyrosine | 2004 |
Platelet glycoprotein IIb/IIIa receptor antagonists in non-ST segment elevation acute coronary syndromes: a review and guide to patient selection.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Contraindications; Coronary Disease; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Patient Selection; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Randomized Controlled Trials as Topic; Risk Factors; Tirofiban; Tyrosine | 2005 |
Immune thrombocytopenia caused by glycoprotein IIb/IIIa inhibitors.
Topics: Abciximab; Antibodies, Monoclonal; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Thrombocytopenia; Tirofiban; Tyrosine | 2005 |
Antiplatelet agents in patients undergoing percutaneous coronary intervention: how many and how much?
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Clinical Trials as Topic; Clopidogrel; Eptifibatide; Hirudins; Humans; Immunoglobulin Fab Fragments; Peptide Fragments; Peptides; Platelet Aggregation Inhibitors; Recombinant Proteins; Ticlopidine; Tirofiban; Tyrosine | 2005 |
Frequency and management of thrombocytopenia with the glycoprotein IIb/IIIa receptor antagonists.
Topics: Abciximab; Adrenal Cortex Hormones; Antibodies, Monoclonal; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Immunoglobulins, Intravenous; Myocardial Ischemia; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prevalence; Thrombocytopenia; Tirofiban; Tyrosine | 2006 |
Thrombocytopenia associated with the use of GPIIb/IIIa inhibitors: position paper of the ISTH working group on thrombocytopenia and GPIIb/IIIa inhibitors.
Topics: Abciximab; Antibodies, Monoclonal; Autoantibodies; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Thrombocytopenia; Tirofiban; Tyrosine | 2006 |
Current strategies with eptifibatide and other antiplatelet agents in percutaneous coronary intervention and acute coronary syndromes.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Coronary Disease; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Tirofiban; Tyrosine | 2005 |
[Antithrombotic treatment of acute coronary syndromes without ST-segment elevation].
Topics: Abciximab; Antibodies, Monoclonal; Aspirin; Clopidogrel; Eptifibatide; Fibrinolytic Agents; Humans; Immunoglobulin Fab Fragments; Myocardial Infarction; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Risk Factors; Syndrome; Ticlopidine; Tirofiban; Tyrosine | 2006 |
[Update on antithrombotic treatments in arterial diseases].
Topics: Abciximab; Antibodies, Monoclonal; Anticoagulants; Arteriosclerosis; Aspirin; Dipyridamole; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Peptides; Platelet Aggregation Inhibitors; Pyridines; Thrombosis; Tirofiban; Treatment Outcome; Tyrosine | 2007 |
Emergency coronary artery bypass grafting in patients with acute myocardial infarction treated with glycoprotein IIb/IIIa receptor inhibitors.
Topics: Abciximab; Antibodies, Monoclonal; Combined Modality Therapy; Coronary Artery Bypass; Dose-Response Relationship, Drug; Drug Administration Schedule; Emergency Treatment; Eptifibatide; Female; Humans; Immunoglobulin Fab Fragments; Infusions, Intravenous; Male; Myocardial Infarction; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prognosis; Survival Analysis; Tirofiban; Treatment Outcome; Tyrosine | 2008 |
Meta-analysis of clinical efficacy and bleeding risk with intravenous glycoprotein IIb/IIIa antagonists for percutaneous coronary intervention.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Bleeding Time; Eptifibatide; Female; Hemorrhage; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Myocardial Infarction; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Randomized Controlled Trials as Topic; Reoperation; Thrombocytopenia; Tirofiban; Treatment Outcome; Tyrosine | 2007 |
ST-elevation myocardial infarction: the role of adjunctive antiplatelet therapy.
Topics: Abciximab; Antibodies, Monoclonal; Aspirin; Clopidogrel; Electrocardiography; Eptifibatide; Fibrinolytic Agents; Humans; Immunoglobulin Fab Fragments; Myocardial Infarction; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Pyridines; Ticlopidine; Tirofiban; Tyrosine | 2008 |
Glycoprotein IIb/IIIa antagonists in acute ischaemic stroke: current status and future directions.
Topics: Abciximab; Acute Disease; Animals; Antibodies, Monoclonal; Brain Ischemia; Clinical Trials as Topic; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Stroke; Tirofiban; Tyrosine | 2008 |
Benefits from small molecule administration as compared with abciximab among patients with ST-segment elevation myocardial infarction treated with primary angioplasty: a meta-analysis.
Topics: Abciximab; Angioplasty, Balloon; Antibodies, Monoclonal; Anticoagulants; Confidence Intervals; Coronary Angiography; Eptifibatide; Fibrinolytic Agents; Hematologic Agents; Humans; Immunoglobulin Fab Fragments; Myocardial Infarction; Odds Ratio; Peptides; Platelet Aggregation Inhibitors; Tirofiban; Tyrosine | 2009 |
Risk profile and benefits from Gp IIb-IIIa inhibitors among patients with ST-segment elevation myocardial infarction treated with primary angioplasty: a meta-regression analysis of randomized trials.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Myocardial Infarction; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Randomized Controlled Trials as Topic; Regression Analysis; Risk Assessment; Survival Analysis; Tirofiban; Treatment Outcome; Tyrosine | 2009 |
A comparison of abciximab and small-molecule glycoprotein IIb/IIIa inhibitors in patients undergoing primary percutaneous coronary intervention: a meta-analysis of contemporary randomized controlled trials.
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Eptifibatide; Female; Hemorrhage; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Myocardial Infarction; Odds Ratio; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Randomized Controlled Trials as Topic; Recurrence; Risk Assessment; Risk Factors; Thrombosis; Time Factors; Tirofiban; Treatment Outcome; Tyrosine | 2009 |
Early administration of small-molecule glycoprotein IIb/IIIa inhibitors before primary percutaneous coronary intervention for ST-elevation myocardial infarction: insights from randomized clinical trials.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Myocardial Infarction; Peptides; Platelet Glycoprotein GPIIb-IIIa Complex; Randomized Controlled Trials as Topic; Tirofiban; Tyrosine | 2010 |
Comparison by meta-analysis of eptifibatide and tirofiban to abciximab in patients with ST-elevation myocardial infarction treated with primary percutaneous coronary intervention.
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Electrocardiography; Eptifibatide; Female; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Myocardial Infarction; Peptides; Platelet Aggregation Inhibitors; Tirofiban; Treatment Outcome; Tyrosine | 2010 |
Routine upstream versus selective downstream administration of glycoprotein IIb/IIIa inhibitors in patients with non-ST-elevation acute coronary syndromes: a meta-analysis of randomized trials.
Topics: Acute Coronary Syndrome; Electrocardiography; Eptifibatide; Humans; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Randomized Controlled Trials as Topic; Tirofiban; Tyrosine | 2012 |
Update on glycoprotein IIb/IIIa: role in primary coronary intervention.
Topics: Abciximab; Angioplasty; Animals; Antibodies, Monoclonal; Blood Platelets; Coronary Artery Disease; Coronary Vessels; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Peptides; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Tirofiban; Tyrosine | 2011 |
Upstream use of small-molecule glycoprotein iib/iiia inhibitors in patients with non-ST-segment elevation acute coronary syndromes: a systematic overview of randomized clinical trials.
Topics: Acetates; Acute Coronary Syndrome; Administration, Cutaneous; Angioplasty; Electrocardiography; Eptifibatide; Hemorrhage; Humans; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Postoperative Complications; Randomized Controlled Trials as Topic; Risk; Survival Analysis; Tirofiban; Tyrosine | 2011 |
Current issues with glycoprotein IIb-IIIa antagonists.
Topics: Abciximab; Acute Coronary Syndrome; Antibodies, Monoclonal; Anticoagulants; Eptifibatide; Hemostasis; Humans; Immunoglobulin Fab Fragments; Peptides; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Thrombosis; Tirofiban; Tyrosine | 2011 |
Meta-analysis of randomized controlled trials of intracoronary versus intravenous administration of glycoprotein IIb/IIIa inhibitors during percutaneous coronary intervention for acute coronary syndrome.
Topics: Abciximab; Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Coronary Circulation; Eptifibatide; Hemorrhage; Humans; Immunoglobulin Fab Fragments; Infusions, Intravenous; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Randomized Controlled Trials as Topic; Tirofiban; Tyrosine | 2011 |
Contemporary use of glycoprotein IIb/IIIa inhibitors.
Topics: Abciximab; Acute Coronary Syndrome; Angioplasty; Animals; Antibodies, Monoclonal; Clinical Trials as Topic; Eptifibatide; Fibrinolytic Agents; Humans; Immunoglobulin Fab Fragments; Peptides; Platelet Glycoprotein GPIIb-IIIa Complex; Postoperative Complications; Thrombosis; Tirofiban; Tyrosine | 2012 |
Treatment with tirofiban for acute coronary syndrome (ACS): a systematic review and network analysis.
Topics: Abciximab; Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Dose-Response Relationship, Drug; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Myocardial Infarction; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Tirofiban; Treatment Outcome; Tyrosine | 2012 |
GP IIb/IIIa inhibitors for STEMI: still the gold standard or an old survivor?
Topics: Abciximab; Animals; Antibodies, Monoclonal; Arrhythmias, Cardiac; Eptifibatide; Evidence-Based Medicine; Humans; Immunoglobulin Fab Fragments; Injections, Intravenous; Myocardial Infarction; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Tirofiban; Tyrosine | 2012 |
Glycoprotein IIb/IIIa antagonists.
Topics: Abciximab; Animals; Antibodies, Monoclonal; Blood Platelets; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Tirofiban; Tyrosine | 2012 |
Rescue treatment of thromboembolic complications during endovascular treatment of cerebral aneurysms: a meta-analysis.
Topics: Abciximab; Antibodies, Monoclonal; Endovascular Procedures; Eptifibatide; Fibrinolytic Agents; Humans; Immunoglobulin Fab Fragments; Intracranial Aneurysm; Intraoperative Complications; Male; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Thromboembolism; Thrombolytic Therapy; Tirofiban; Tyrosine | 2015 |
Antiplatelet and anticoagulation agents in acute coronary syndromes: what is the current status and what does the future hold?
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Anticoagulants; Aspirin; Drug Therapy, Combination; Enoxaparin; Eptifibatide; Fondaparinux; Heparin; Hirudins; Humans; Lactones; Peptide Fragments; Peptides; Piperazines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Polysaccharides; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Pyridines; Receptors, Thrombin; Recombinant Proteins; Thiophenes; Ticagrelor; Tirofiban; Tyrosine; Warfarin | 2014 |
Glycoprotein IIb/IIIa inhibitors: The resurgence of tirofiban.
Topics: Abciximab; Acute Coronary Syndrome; Antibodies, Monoclonal; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Practice Guidelines as Topic; Thrombosis; Tirofiban; Tyrosine | 2016 |
Bivalirudin Anticoagulant Therapy With or Without Platelet Glycoprotein IIb/IIIa Inhibitors During Transcatheter Coronary Interventional Procedures: A Meta-Analysis.
Topics: Antithrombins; Cardiac Catheterization; Eptifibatide; Hirudins; Humans; Integrin alpha2; Myocardial Infarction; Peptide Fragments; Peptides; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Recombinant Proteins; Tirofiban; Treatment Outcome; Tyrosine | 2015 |
Effects Of Glycoprotein IIb/IIIa Antagonists: Anti Platelet Aggregation And Beyond.
Topics: Abciximab; Animals; Antibodies, Monoclonal; Blood Platelets; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Peptides; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Randomized Controlled Trials as Topic; Tirofiban; Tyrosine | 2016 |
Efficacy and safety of eptifibatide versus tirofiban in acute coronary syndrome patients: A systematic review and meta-analysis.
Topics: Acute Coronary Syndrome; Eptifibatide; Humans; Myocardial Infarction; Peptides; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Tirofiban; Treatment Outcome; Tyrosine | 2017 |
Efficacy and safety of a bridging strategy that uses intravenous platelet glycoprotein receptor inhibitors for patients undergoing surgery after coronary stent implantation: a meta-analysis.
Topics: Eptifibatide; Humans; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Platelet Membrane Glycoproteins; Stents; Tirofiban; Treatment Outcome; Tyrosine | 2022 |
29 trial(s) available for tyrosine and eptifibatide
| Article | Year |
|---|---|
Glycoprotein IIb/IIIa receptor inhibition in interventional cardiology.
Topics: Abciximab; Administration, Oral; Adult; Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Cardiology; Clinical Trials as Topic; Coronary Disease; Double-Blind Method; Embolism; Eptifibatide; Female; Fibrinolytic Agents; Follow-Up Studies; Forecasting; Hemorrhage; Humans; Immunoglobulin Fab Fragments; Male; Meta-Analysis as Topic; Middle Aged; Multicenter Studies as Topic; Myocardial Infarction; Peptides; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prospective Studies; Risk; Stents; Structure-Activity Relationship; Tirofiban; Treatment Outcome; Tyrosine | 1999 |
Variable responses to inhibition of fibrinogen binding induced by tirofiban and eptifibatide in blood from healthy subjects.
Topics: Adenosine Diphosphate; Adult; Dose-Response Relationship, Drug; Eptifibatide; Female; Fibrinogen; Flow Cytometry; Humans; Male; Middle Aged; P-Selectin; Peptides; Platelet Aggregation Inhibitors; Protein Binding; Tirofiban; Tyrosine | 1999 |
[Inhibitors of GPIIb/IIIa platelet receptors].
Topics: Abciximab; Acetates; Antibodies, Monoclonal; Cerebrovascular Disorders; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Myocardial Infarction; Peptides; Platelet Activation; Platelet Adhesiveness; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Thrombocytopenia; Tirofiban; Tyrosine | 1999 |
Time course, magnitude, and consistency of platelet inhibition by abciximab, tirofiban, or eptifibatide in patients with unstable angina pectoris undergoing percutaneous coronary intervention.
Topics: Abciximab; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Blood Platelets; Eptifibatide; Female; Follow-Up Studies; Humans; Immunoglobulin Fab Fragments; Injections, Intravenous; Male; Peptides; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Count; Platelet Glycoprotein GPIIb-IIIa Complex; Time Factors; Tirofiban; Treatment Outcome; Tyrosine | 1999 |
High platelet count in platelet-rich plasma reduces measured platelet inhibition by abciximab but not tirofiban nor eptifibatide glycoprotein IIb/IIIa receptor antagonists.
Topics: Abciximab; Angina, Unstable; Antibodies, Monoclonal; Confounding Factors, Epidemiologic; Eptifibatide; Female; Humans; Immunoglobulin Fab Fragments; Male; Peptides; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Count; Platelet Function Tests; Platelet Glycoprotein GPIIb-IIIa Complex; Tirofiban; Tyrosine | 2000 |
Combining low-molecular-weight heparin and glycoprotein IIb/IIIa antagonists for the treatment of acute coronary syndromes: the NICE 3 story. National Investigators Collaborating on Enoxaparin.
Topics: Abciximab; Acute Disease; Antibodies, Monoclonal; Anticoagulants; Coronary Disease; Drug Therapy, Combination; Enoxaparin; Eptifibatide; Feasibility Studies; Humans; Immunoglobulin Fab Fragments; Injections, Intravenous; North America; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Safety; Tirofiban; Tyrosine | 2000 |
Antiplatelet effects of abciximab, tirofiban and eptifibatide in patients undergoing coronary stenting.
Topics: Abciximab; Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Coronary Disease; Eptifibatide; Female; Humans; Immunoglobulin Fab Fragments; Infusions, Intravenous; Male; Middle Aged; Peptides; Platelet Aggregation; Platelet Aggregation Inhibitors; Stents; Tirofiban; Tyrosine | 2001 |
Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention: results of the GOLD (AU-Assessing Ultegra) multicenter study.
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Blood Platelets; Cohort Studies; Eptifibatide; Female; Heart Diseases; Humans; Immunoglobulin Fab Fragments; Logistic Models; Male; Multivariate Analysis; Peptides; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prospective Studies; Risk Factors; Time Factors; Tirofiban; Tyrosine | 2001 |
Randomized comparison of ticlopidine and clopidogrel after intracoronary stent implantation in a broad patient population.
Topics: Abciximab; Antibodies, Monoclonal; Clopidogrel; Coronary Disease; Coronary Thrombosis; Eptifibatide; Exanthema; Female; Gastrointestinal Diseases; Hemorrhage; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Neutropenia; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Stents; Thrombocytopenia; Ticlopidine; Tirofiban; Tyrosine | 2001 |
Increased reperfusion by glycoprotein IIb/IIIa receptor antagonist administration in case of unsuccessful and failed thrombolysis in patients with acute myocardial infarction: a pilot study.
Topics: Abciximab; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Coronary Angiography; Drug Therapy, Combination; Eptifibatide; Female; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Myocardial Infarction; Myocardial Reperfusion; Peptides; Pilot Projects; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Research Design; Risk Factors; Single-Blind Method; Thrombolytic Therapy; Tirofiban; Tissue Plasminogen Activator; Tyrosine | 2001 |
Effectiveness of tirofiban, eptifibatide, and abciximab in minimizing myocardial necrosis during percutaneous coronary intervention (TEAM pilot study).
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Cardiac Catheterization; Cardiomyopathies; Combined Modality Therapy; Creatine Kinase; Creatine Kinase, MB Form; Eptifibatide; Female; Humans; Immunoglobulin Fab Fragments; Incidence; Isoenzymes; Male; Middle Aged; Myocardial Infarction; Necrosis; Peptides; Pilot Projects; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Predictive Value of Tests; Stroke Volume; Tirofiban; Treatment Outcome; Troponin I; Tyrosine | 2002 |
Randomized COMparison of platelet inhibition with abciximab, tiRofiban and eptifibatide during percutaneous coronary intervention in acute coronary syndromes: the COMPARE trial. Comparison Of Measurements of Platelet aggregation with Aggrastat, Reopro, an
Topics: Abciximab; Acute Disease; Aged; Amino Acid Chloromethyl Ketones; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Citric Acid; Coronary Disease; Eptifibatide; Female; Humans; Immunoglobulin Fab Fragments; Kinetics; Male; Middle Aged; Myocardial Infarction; Peptides; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Syndrome; Tirofiban; Tyrosine | 2002 |
Platelet glycoprotein IIb/IIIa receptor blockade improves vascular nitric oxide bioavailability in patients with coronary artery disease.
Topics: Acetylcholine; Biological Availability; Blood Flow Velocity; Blood Platelets; Coronary Artery Disease; Endothelium, Vascular; Enzyme Inhibitors; Eptifibatide; Forearm; Humans; Male; Middle Aged; Nitric Oxide; Nitric Oxide Donors; omega-N-Methylarginine; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Plethysmography; Tirofiban; Tyrosine; Vasodilation; Vasodilator Agents; Vasomotor System | 2003 |
Desmopressin antagonizes the in vitro platelet dysfunction induced by GPIIb/IIIa inhibitors and aspirin.
Topics: Abciximab; Adenosine Diphosphate; Adult; Antibodies, Monoclonal; Aspirin; Collagen; Cross-Over Studies; Deamino Arginine Vasopressin; Dose-Response Relationship, Drug; Double-Blind Method; Epinephrine; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Male; Peptides; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Tirofiban; Tyrosine | 2003 |
Combining enoxaparin and glycoprotein IIb/IIIa antagonists for the treatment of acute coronary syndromes: final results of the National Investigators Collaborating on Enoxaparin-3 (NICE-3) study.
Topics: Abciximab; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Coronary Disease; Drug Therapy, Combination; Enoxaparin; Eptifibatide; Female; Fibrinolytic Agents; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Myocardial Infarction; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Syndrome; Thrombolytic Therapy; Tirofiban; Treatment Outcome; Tyrosine | 2003 |
Use of lepirudin during percutaneous vascular interventions in patients with heparin-induced thrombocytopenia.
Topics: Abciximab; Angioplasty, Balloon; Antibodies, Monoclonal; Anticoagulants; Drug Therapy, Combination; Eptifibatide; Female; Heparin; Hirudins; Humans; Immunoglobulin Fab Fragments; Male; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prospective Studies; Recombinant Proteins; Thrombocytopenia; Tirofiban; Treatment Outcome; Tyrosine | 2003 |
Blockade of GPIIb/IIIa by eptifibatide and tirofiban does not alter tissue factor induced thrombin generation in human endotoxemia.
Topics: Adult; Biomarkers; Blood Coagulation; Double-Blind Method; Endotoxemia; Enzyme-Linked Immunosorbent Assay; Eptifibatide; Humans; Male; Peptides; Platelet Glycoprotein GPIIb-IIIa Complex; RNA, Messenger; Thrombin; Thromboplastin; Tirofiban; Tyrosine | 2003 |
Prospective evaluation of the relationship between platelet-leukocyte conjugate formation and recurrent myocardial ischemia in patients with acute coronary syndromes.
Topics: Adenosine Diphosphate; Adrenergic beta-Antagonists; Aged; Angina, Unstable; Arachidonic Acid; Aspirin; Blood Platelets; C-Reactive Protein; Cell Aggregation; Drug Resistance; Eptifibatide; Female; Heparin; Humans; Leukocytes; Male; Middle Aged; Monocytes; Multivariate Analysis; Myocardial Infarction; Myocardial Ischemia; Neutrophils; Patient Selection; Peptides; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prospective Studies; Receptors, Thrombin; Recurrence; ROC Curve; Tirofiban; Treatment Outcome; Troponin I; Tyrosine | 2004 |
Variable inhibition of high-shear-induced platelet plug formation by eptifibatide and tirofiban under conditions of platelet activation and high von Willebrand release: a randomized, placebo-controlled, clinical trial.
Topics: Adolescent; Adult; Calcium; Double-Blind Method; Eptifibatide; Hemorheology; Humans; Male; Peptides; Platelet Activation; Platelet Adhesiveness; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Platelet Glycoprotein GPIIb-IIIa Complex; Tirofiban; Tyrosine; von Willebrand Factor | 2004 |
Comparative pharmacodynamic evaluation of eptifibatide and tirofiban HCl in patients undergoing percutaneous coronary intervention (the TAM1 Study).
Topics: Angioplasty, Balloon, Coronary; Arkansas; Coronary Artery Disease; Eptifibatide; Female; Humans; Infusions, Intravenous; Male; Mississippi; Peptides; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Tennessee; Tirofiban; Tyrosine; United States | 2004 |
Comparison of enoxaparin versus heparin during elective percutaneous coronary intervention performed with either eptifibatide or tirofiban (the ACTION Trial).
Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Drug Therapy, Combination; Elective Surgical Procedures; Enoxaparin; Eptifibatide; Female; Fibrinolytic Agents; Heparin; Humans; Integrin alpha2; Integrin beta3; Male; Membrane Glycoproteins; Middle Aged; Peptides; Platelet Aggregation; Platelet Aggregation Inhibitors; Prospective Studies; Thrombosis; Tirofiban; Treatment Outcome; Tyrosine | 2005 |
The impact of GP IIb/IIIa inhibitors during primary percutaneous coronary intervention in acute myocardial infarction patients.
Topics: Abciximab; Acute Disease; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Coronary Angiography; Eptifibatide; Female; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Myocardial Infarction; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Stents; Tirofiban; Treatment Outcome; Tyrosine | 2005 |
Impact of platelet glycoprotein IIb/IIIa Inhibition on the paclitaxel-eluting stent in patients with stable or unstable angina pectoris or provocable myocardial ischemia (a TAXUS IV substudy).
Topics: Abciximab; Angina, Unstable; Antibodies, Monoclonal; Antineoplastic Agents, Phytogenic; Coated Materials, Biocompatible; Coronary Angiography; Coronary Restenosis; Creatine Kinase; Creatine Kinase, MB Form; Double-Blind Method; Drug Interactions; Eptifibatide; Female; Follow-Up Studies; Humans; Immunoglobulin Fab Fragments; Isoenzymes; Male; Middle Aged; Myocardial Ischemia; Myocardial Revascularization; Paclitaxel; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Stents; Tirofiban; Treatment Outcome; Tyrosine | 2005 |
Optimal platelet inhibition in patients undergoing PCI: data from the Multicenter Registry of High-Risk Percutaneous Coronary Intervention and Adequate Platelet Inhibition (MR PCI) study.
Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Clopidogrel; Eptifibatide; Humans; Myocardial Infarction; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Registries; Ticlopidine; Tirofiban; Tyrosine | 2007 |
Use of glycoprotein IIb/IIIa inhibitors in primary percutaneous coronary intervention: insights from the APEX-AMI trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Eptifibatide; Female; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Myocardial Infarction; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Retrospective Studies; Tirofiban; Tyrosine | 2010 |
Long-term efficacy of high-dose tirofiban versus double-bolus eptifibatide in patients undergoing percutaneous coronary intervention.
Topics: Aged; Angioplasty; Eptifibatide; Female; Humans; Male; Middle Aged; Myocardial Ischemia; Peptides; Platelet Aggregation Inhibitors; Tirofiban; Treatment Outcome; Tyrosine | 2011 |
Comparative effectiveness of upstream glycoprotein IIb/IIIa inhibitors in patients with moderate- and high-risk acute coronary syndromes: an Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) substudy.
Topics: Acute Coronary Syndrome; Aged; Comparative Effectiveness Research; Coronary Angiography; Eptifibatide; Female; Humans; Male; Middle Aged; Multivariate Analysis; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Propensity Score; Tirofiban; Treatment Outcome; Tyrosine | 2014 |
Impact of glycoprotein IIb/IIIa inhibitors on the efficacy and safety of ticagrelor compared with clopidogrel in patients with acute coronary syndromes: Analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial.
Topics: Abciximab; Acute Coronary Syndrome; Adenosine; Aged; Antibodies, Monoclonal; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Drug-Eluting Stents; Eptifibatide; Female; Graft Occlusion, Vascular; Hemorrhage; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Myocardial Infarction; Peptides; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Purinergic P2Y Receptor Antagonists; Stroke; Thrombosis; Ticagrelor; Ticlopidine; Tirofiban; Tyrosine | 2016 |
A randomized trial assessing the impact of three different glycoprotein IIb/IIIa antagonists on glycoprotein IIb/IIIa platelet receptor inhibition and clinical endpoints in patients with acute coronary syndromes.
Topics: Abciximab; Acute Coronary Syndrome; Adenosine; Aged; Antibodies, Monoclonal; Blood Platelets; Clopidogrel; Drug Therapy, Combination; Eptifibatide; Female; Hemorrhage; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; New South Wales; Peptides; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Platelet Function Tests; Platelet Glycoprotein GPIIb-IIIa Complex; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Risk Factors; Ticagrelor; Ticlopidine; Time Factors; Tirofiban; Treatment Outcome; Tyrosine | 2016 |
113 other study(ies) available for tyrosine and eptifibatide
| Article | Year |
|---|---|
In search of a superaspirin for the heart.
Topics: Abciximab; Acetates; Antibodies, Monoclonal; Anticoagulants; Coronary Disease; Eptifibatide; Fibrinolytic Agents; Humans; Immunoglobulin Fab Fragments; Peptides; Platelet Aggregation Inhibitors; Tirofiban; Tyrosine | 1997 |
Advances in antiplatelet therapy for acute coronary syndromes.
Topics: Abciximab; Antibodies, Monoclonal; Coronary Disease; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Tirofiban; Tyrosine | 1998 |
Two i.v. antiplatelet agents marketed for coronary disease.
Topics: Coronary Disease; Drug Approval; Eptifibatide; Humans; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Tirofiban; Tyrosine; United States; United States Food and Drug Administration | 1998 |
Two new antiplatelet drugs for angioplasty and acute coronary syndromes.
Topics: Abciximab; Acute Disease; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Coronary Disease; Eptifibatide; Hemorrhage; Humans; Immunoglobulin Fab Fragments; Peptides; Platelet Aggregation Inhibitors; Premedication; Syndrome; Tirofiban; Tyrosine | 1998 |
Super-aspirins in severe angina.
Topics: Angina, Unstable; Aspirin; Drug Therapy, Combination; Eptifibatide; Fibrinolytic Agents; Heparin; Humans; Peptides; Platelet Aggregation Inhibitors; Tirofiban; Tyrosine | 1998 |
New drugs blast budgets. Patients benefit; hospital pharmacies weigh options.
Topics: Abciximab; Angina Pectoris; Antibodies, Monoclonal; Anticoagulants; Drug Approval; Drug Costs; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Peptides; Pharmacy Service, Hospital; Tirofiban; Tyrosine; United States; United States Food and Drug Administration | 1998 |
GP IIb/IIIa inhibitors: an evidence-based approach to their use.
Topics: Abciximab; Angina, Unstable; Antibodies, Monoclonal; Cost-Benefit Analysis; Disease Management; Drug Costs; Eptifibatide; Evidence-Based Medicine; Humans; Immunoglobulin Fab Fragments; Myocardial Infarction; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Tirofiban; Tyrosine; United States | 1999 |
Differences among the parenteral platelet glycoprotein IIb/IIIa inhibitors and implications for treatment.
Topics: Abciximab; Antibodies, Monoclonal; Clinical Trials as Topic; Coronary Disease; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Peptides; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Tirofiban; Tyrosine | 1999 |
Abciximab, eptifibatide, and tirofiban: comparison of parenteral glycoprotein IIb/IIIa inhibitors.
Topics: Abciximab; Antibodies, Monoclonal; Anticoagulants; Clinical Trials as Topic; Coronary Disease; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Infusions, Parenteral; Myocardial Infarction; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Thrombosis; Tirofiban; Tyrosine | 1999 |
A symposium: safety issues concerning the use of glycoprotein IIb-IIIa inhibitors in the management of acute coronary syndromes.
Topics: Abciximab; Acute Disease; Angina, Unstable; Antibodies, Monoclonal; Anticoagulants; Coronary Disease; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Myocardial Infarction; Myocardial Ischemia; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Safety; Tirofiban; Tyrosine | 1999 |
The newest critical care drugs. Part 2.
Topics: Critical Care; Drug Interactions; Drug Monitoring; Eptifibatide; Humans; Peptides; Platelet Aggregation Inhibitors; Tirofiban; Tyrosine | 1999 |
IIb's are not IIb's.
Topics: Abciximab; Antibodies, Monoclonal; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Myocardial Infarction; Peptides; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Randomized Controlled Trials as Topic; Tirofiban; Tyrosine; Vitronectin | 2000 |
Beyond aspirin: how glycoprotein inhibitors ease acute coronary syndromes.
Topics: Abciximab; Acute Disease; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Combined Modality Therapy; Coronary Disease; Drug Monitoring; Eptifibatide; Female; Humans; Immunoglobulin Fab Fragments; Middle Aged; Nursing Assessment; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Tirofiban; Tyrosine | 1999 |
What have We learned from ESPRIT? What will we learn from TARGET?
Topics: Abciximab; Antibodies, Monoclonal; Anticoagulants; Clopidogrel; Cohort Studies; Eptifibatide; Fibrinolytic Agents; Heparin; Humans; Immunoglobulin Fab Fragments; Myocardial Infarction; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Randomized Controlled Trials as Topic; Stents; Ticlopidine; Tirofiban; Tyrosine | 2000 |
Inhibition of platelet-dependent prothrombinase activity and thrombin generation by glycoprotein IIb/IIIa receptor-directed antagonists: potential contributing mechanism of benefit in acute coronary syndromes.
Topics: Abciximab; Acute Disease; Antibodies, Monoclonal; Anticoagulants; Blood Platelets; Coronary Disease; Dose-Response Relationship, Drug; Eptifibatide; Heparin; Humans; Immunoglobulin Fab Fragments; Kinetics; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Thrombin; Thromboplastin; Tirofiban; Tyrosine | 2000 |
Differential antiplatelet efficacy for various GPIIb/IIIa antagonists: role of plasma calcium levels.
Topics: Abciximab; Alanine; Amidines; Analysis of Variance; Antibodies, Monoclonal; Anticoagulants; Blood Platelets; Calcium; Citric Acid; Eptifibatide; Fibrinogen; Heparin; Humans; Immunoglobulin Fab Fragments; Iodine Radioisotopes; Isoxazoles; Peptides; Platelet Activation; Platelet Aggregation; Platelet Glycoprotein GPIIb-IIIa Complex; Protein Binding; Pyrrolidines; Tirofiban; Tyrosine | 2000 |
GPIIb-IIIa antagonist-induced reduction in platelet surface factor V/Va binding and phosphatidylserine expression in whole blood.
Topics: Abciximab; Antibodies, Monoclonal; Blood Platelets; Collagen; Dose-Response Relationship, Drug; Eptifibatide; Factor V; Flow Cytometry; Humans; Immunoglobulin Fab Fragments; Infant, Newborn; Membrane Proteins; Peptides; Phosphatidylserines; Platelet Glycoprotein GPIIb-IIIa Complex; Protein Binding; Thrombasthenia; Thrombin; Tirofiban; Tyrosine | 2000 |
Platelets and coronary intervention: some practical precautions.
Topics: Abciximab; Antibodies, Monoclonal; Coronary Disease; Drug Monitoring; Eptifibatide; Female; Humans; Immunoglobulin Fab Fragments; Incidence; Male; Peptides; Platelet Aggregation Inhibitors; Prognosis; Risk Assessment; Thrombocytopenia; Tirofiban; Tyrosine | 2000 |
[Therapy of acute coronary syndrome with glycoprotein IIb/IIIa antagonists].
Topics: Abciximab; Acute Disease; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Aspirin; Atherectomy; Clinical Trials as Topic; Combined Modality Therapy; Coronary Disease; Eptifibatide; Fibrinolytic Agents; Heparin; Humans; Immunoglobulin Fab Fragments; Myocardial Infarction; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Randomized Controlled Trials as Topic; Syndrome; Tirofiban; Tyrosine; United States; United States Food and Drug Administration | 2000 |
[New thrombocyte aggregation inhibitor in therapy of unstable angina].
Topics: Abciximab; Angina, Unstable; Antibodies, Monoclonal; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Myocardial Infarction; Peptides; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Tirofiban; Tyrosine | 2000 |
A comparative study of light transmission aggregometry and automated bedside platelet function assays in patients undergoing percutaneous coronary intervention and receiving abciximab, eptifibatide, or tirofiban.
Topics: Abciximab; Aged; Angioplasty, Balloon; Antibodies, Monoclonal; Blood Platelets; Eptifibatide; Female; Humans; Immunoglobulin Fab Fragments; Light; Male; Middle Aged; Peptides; Physiology; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Platelet Glycoprotein GPIIb-IIIa Complex; Point-of-Care Systems; Tirofiban; Tyrosine | 2001 |
Effect of Ca2+ chelation on the platelet inhibitory ability of the GPIIb/IIIa antagonists abciximab, eptifibatide and tirofiban.
Topics: Abciximab; Antibodies, Monoclonal; Anticoagulants; Calcium; Chelating Agents; Citric Acid; Dose-Response Relationship, Drug; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Kinetics; Peptides; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Tirofiban; Tyrosine | 2001 |
Unexpected flow cytometric results with two small GPIIb/IIIa blockers: eptifibatide and tirofiban.
Topics: Antibodies, Monoclonal; Drug Monitoring; Eptifibatide; Flow Cytometry; Humans; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Tirofiban; Tyrosine | 2001 |
[Pathophysiology of platelet activation and pharmacology of GPIIb/IIIa inhibitors].
Topics: Abciximab; Antibodies, Monoclonal; Aspirin; Blood Platelets; Clopidogrel; Eptifibatide; Fibrinolytic Agents; Humans; Immunoglobulin Fab Fragments; Peptides; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Risk Factors; Ticlopidine; Tirofiban; Tyrosine | 2001 |
Monitoring platelet function in glycoprotein IIB/IIIA inhibitor therapy.
Topics: Abciximab; Antibodies, Monoclonal; Eptifibatide; Heart Diseases; Humans; Immunoglobulin Fab Fragments; Peptides; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Tirofiban; Tyrosine | 2001 |
Glycoprotein IIb/IIIa inhibitors: more different than alike?
Topics: Abciximab; Antibodies, Monoclonal; Coronary Disease; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Tirofiban; Tyrosine | 2001 |
Eptifibatide and 7E3, but not tirofiban, inhibit alpha(v)beta(3) integrin-mediated binding of smooth muscle cells to thrombospondin and prothrombin.
Topics: Abciximab; Antibodies, Monoclonal; Binding, Competitive; Cell Adhesion; Cell Division; Cell Line; Cells, Cultured; Dimerization; Dose-Response Relationship, Drug; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Muscle, Smooth, Vascular; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prothrombin; Receptors, Vitronectin; Thrombospondin 1; Thrombospondins; Tirofiban; Tyrosine; Vitronectin | 2001 |
Comparative efficacy of fibrinogen and platelet supplementation on the in vitro reversibility of competitive glycoprotein IIb/IIIa (alphaIIb/beta3) receptor-directed platelet inhibition.
Topics: Adult; Cells, Cultured; Dose-Response Relationship, Drug; Eptifibatide; Fibrinogen; Humans; Middle Aged; Peptides; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Platelet Transfusion; Reference Values; Tirofiban; Tyrosine | 2001 |
Differential inhibition of adenosine diphosphate- versus thrombin receptor-activating peptide-stimulated platelet fibrinogen binding by abciximab due to different glycoprotein IIb/IIIa activation kinetics.
Topics: Abciximab; Adenosine Diphosphate; Antibodies, Monoclonal; Biotinylation; Depression, Chemical; Dose-Response Relationship, Drug; Eptifibatide; Fibrinogen; Humans; Immunoglobulin Fab Fragments; Kinetics; Peptides; Platelet Adhesiveness; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Protein Binding; Proteins; Receptors, Thrombin; Tirofiban; Tyrosine | 2001 |
Short-term comparative outcomes associated with the use of GP IIb/IIIa antagonists in patients undergoing coronary intervention.
Topics: Abciximab; Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Creatine Kinase; Drug Therapy, Combination; Eptifibatide; Female; Fibrinolytic Agents; Hemorrhage; Heparin; Humans; Immunoglobulin Fab Fragments; Length of Stay; Male; Middle Aged; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prospective Studies; Recurrence; Retrospective Studies; Survival Rate; Tirofiban; Treatment Outcome; Tyrosine | 2001 |
Administration of abciximab to patients receiving tirofiban or eptifibatide: effect on platelet function.
Topics: Abciximab; Antibodies, Monoclonal; Blood Platelets; Drug Therapy, Combination; Eptifibatide; Female; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Peptides; Platelet Aggregation; Platelet Glycoprotein GPIIb-IIIa Complex; Tirofiban; Tyrosine | 2001 |
A risk stratification scheme for selection of a glycoprotein IIb/IIIa inhibitor during percutaneous coronary intervention based on clinical and angiographic criteria.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Coronary Angiography; Creatine Kinase; Creatine Kinase, MB Form; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Isoenzymes; Myocardial Infarction; Peptides; Platelet Glycoprotein GPIIb-IIIa Complex; Prospective Studies; Risk Factors; Tirofiban; Tyrosine | 2001 |
Differential effects of citrate versus PPACK anticoagulation on measured platelet inhibition by abciximab, eptifibatide and tirofiban.
Topics: Abciximab; Amino Acid Chloromethyl Ketones; Antibodies, Monoclonal; Anticoagulants; Antithrombins; Blood Specimen Collection; Calcium; Chelating Agents; Citric Acid; Drug Interactions; Drug Monitoring; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Peptides; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Tirofiban; Tyrosine | 2001 |
Glycoprotein IIb/IIIa receptor blockers in acute coronary syndromes.
Topics: Abciximab; Antibodies, Monoclonal; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Myocardial Infarction; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Practice Guidelines as Topic; Survival Analysis; Tirofiban; Treatment Outcome; Troponin T; Tyrosine | 2001 |
Platelet inhibition after glycoprotein IIb/IIIa inhibitor therapy.
Topics: Abciximab; Antibodies, Monoclonal; Blood Platelets; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Thrombosis; Tirofiban; Tyrosine | 2001 |
Platelet glycoprotein IIb/IIIa inhibitor effect examined in 2 studies.
Topics: Acetates; Acute Disease; Angina, Unstable; Clinical Trials as Topic; Coronary Artery Bypass; Coronary Disease; Eptifibatide; Humans; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prognosis; Syndrome; Treatment Outcome; Tyrosine | 2002 |
Eptifibatide and 7E3, but not tirofiban, inhibit alpha(v)beta3 integrin-mediated binding of smooth muscle cells to thrombospondin and prothrombin.
Topics: Antibodies, Monoclonal; Eptifibatide; Humans; Muscle, Smooth, Vascular; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Protein Binding; Prothrombin; Receptors, Vitronectin; Thrombospondins; Tirofiban; Tyrosine | 2002 |
Duration of action of GpIIb-IIIa antagonists.
Topics: Abciximab; Antibodies, Monoclonal; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Peptides; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Time Factors; Tirofiban; Tyrosine | 2000 |
Comparative efficacy of fibrinogen and platelet supplementation on the in vitro reversibility of competitive glycoprotein IIb/IIIa receptor-directed platelet inhibition.
Topics: Adult; Blood Platelets; Eptifibatide; Fibrinogen; Fibrinolytic Agents; Humans; Linear Models; Middle Aged; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Tirofiban; Tyrosine | 2002 |
Gender differences in clinical outcome after coronary artery stenting with use of glycoprotein IIb/IIIa inhibitors.
Topics: Abciximab; Aged; Antibodies, Monoclonal; Cardiac Catheterization; Coronary Disease; Eptifibatide; Female; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Sex Factors; Stents; Tirofiban; Treatment Outcome; Tyrosine | 2002 |
Comparative antithrombotic effects of magnesium sulfate and the platelet glycoprotein IIb/IIIa inhibitors tirofiban and eptifibatide in a canine model of stent thrombosis.
Topics: Animals; Arteriovenous Shunt, Surgical; Bleeding Time; Blood Coagulation; Blood Pressure; Dogs; Eptifibatide; Fibrinolytic Agents; Heart Rate; Heparin; Magnesium Sulfate; P-Selectin; Peptides; Platelet Aggregation; Platelet Glycoprotein GPIIb-IIIa Complex; Stents; Thrombosis; Time Factors; Tirofiban; Tyrosine | 2002 |
Glycoprotein IIb/IIIa inhibitors.
Topics: Abciximab; Antibodies, Monoclonal; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Tirofiban; Tyrosine | 2002 |
Cost efficacy of platelet glycoprotein IIb/IIIa antagonists in clinical trials and clinical practice.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Cardiovascular Diseases; Clinical Trials as Topic; Coronary Thrombosis; Cost-Benefit Analysis; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Practice Patterns, Physicians'; Tirofiban; Tyrosine | 2002 |
Low incidence of paradoxical platelet activation by glycoprotein IIb/IIIa inhibitors.
Topics: Abciximab; Adenosine Diphosphate; Adult; Antibodies, Monoclonal; Antigens, Human Platelet; Case-Control Studies; Coronary Artery Disease; Eptifibatide; Female; Genotype; Humans; Immunoglobulin Fab Fragments; Incidence; Integrin beta3; Male; Middle Aged; P-Selectin; Peptides; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Polymorphism, Genetic; Tirofiban; Tyrosine | 2002 |
Development of a non-human primate sub-clinical model of heparin-induced thrombocytopenia: platelet responses to human anti-heparin-platelet factor 4 antibodies.
Topics: Abciximab; Animals; Antibodies, Monoclonal; Antibody Specificity; Autoantibodies; Blood Platelets; Eptifibatide; Heparin; Humans; Immunoglobulin Fab Fragments; Macaca mulatta; Models, Animal; Peptides; Phylogeny; Plasmapheresis; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Factor 4; Platelet Glycoprotein GPIIb-IIIa Complex; Purpura, Thrombocytopenic, Idiopathic; Serotonin; Species Specificity; Tirofiban; Tyrosine | 2002 |
Acute thrombocytopenia after treatment with tirofiban or eptifibatide is associated with antibodies specific for ligand-occupied GPIIb/IIIa.
Topics: Acute Disease; Aged; Autoantibodies; Calcium; Case-Control Studies; Cross Reactions; Epitopes; Eptifibatide; Female; Humans; Ligands; Male; Middle Aged; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Thrombocytopenia; Tirofiban; Tyrosine | 2002 |
ACC/AHA guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction--2002: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidel
Topics: Abciximab; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Biomarkers; Clopidogrel; Disease Management; Drug Therapy, Combination; Electrocardiography; Eptifibatide; Female; Health Behavior; Hemorrhage; Humans; Hypolipidemic Agents; Immunoglobulin Fab Fragments; Male; Myocardial Infarction; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Ticlopidine; Tirofiban; Tyrosine | 2002 |
Recombinant factor VIIa enhances deposition of platelets with congenital or acquired alpha IIb beta 3 deficiency to endothelial cell matrix and collagen under conditions of flow via tissue factor-independent thrombin generation.
Topics: Abciximab; Adult; Antibodies, Monoclonal; Blood Platelets; Cells, Cultured; Collagen; Drug Evaluation, Preclinical; Endothelium, Vascular; Eptifibatide; Extracellular Matrix; Factor VIIa; Factor X; Hemorheology; Humans; Immunoglobulin Fab Fragments; Oligopeptides; Peptides; Platelet Adhesiveness; Platelet Glycoprotein GPIIb-IIIa Complex; Prothrombin; Recombinant Proteins; Tetradecanoylphorbol Acetate; Thrombasthenia; Thrombin; Thromboplastin; Tirofiban; Tyrosine | 2003 |
Comparative analysis of various platelet glycoprotein IIb/IIIa antagonists on shear-induced platelet activation and adhesion.
Topics: Abciximab; Alanine; Amidines; Analysis of Variance; Antibodies, Monoclonal; Anticoagulants; Aspirin; Cell Aggregation; Dose-Response Relationship, Drug; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Isoxazoles; Peptides; Platelet Activation; Platelet Adhesiveness; Platelet Glycoprotein GPIIb-IIIa Complex; Pyrrolidines; Rheology; Shear Strength; Temperature; Tirofiban; Tyrosine | 2002 |
Thrombocytopenia following treatment with platelet glycoprotein IIb/IIIa inhibitors.
Topics: Abciximab; Antibodies, Monoclonal; Autoantibodies; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Peptides; Platelet Glycoprotein GPIIb-IIIa Complex; Thrombocytopenia; Tirofiban; Tyrosine | 2003 |
Comparison of the i-STAT handheld activated clotting time with the Hemochron activated clotting time during and after percutaneous coronary intervention.
Topics: Abciximab; Analysis of Variance; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Coronary Disease; Drug Monitoring; Eptifibatide; Heparin; Humans; Immunoglobulin Fab Fragments; Linear Models; Peptides; Platelet Aggregation Inhibitors; Point-of-Care Systems; Predictive Value of Tests; Tirofiban; Treatment Outcome; Tyrosine; Whole Blood Coagulation Time | 2003 |
Access to new cardiovascular therapies in Canadian hospitals: a national survey of the formulary process.
Topics: Abciximab; Antibodies, Monoclonal; Canada; Cardiovascular Agents; Clopidogrel; Dalteparin; Data Collection; Drug Utilization; Enoxaparin; Eptifibatide; Formularies, Hospital as Topic; Health Services Accessibility; Hematologic Agents; Humans; Immunoglobulin Fab Fragments; Peptides; Pharmacy and Therapeutics Committee; Ticlopidine; Tirofiban; Tyrosine | 2003 |
Inhibitory effects of glycoprotein IIb/IIIa antagonists and aspirin on the release of soluble CD40 ligand during platelet stimulation.
Topics: Abciximab; Antibodies, Monoclonal; Aspirin; Blood Platelets; CD40 Ligand; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Kinetics; Peptides; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Tirofiban; Tyrosine | 2003 |
[New antiaggregants and their importance for the practitioner].
Topics: Abciximab; Administration, Oral; Adult; Anesthesia, Spinal; Antibodies, Monoclonal; Aspirin; Cardiovascular Diseases; Clinical Trials as Topic; Clopidogrel; Contraindications; Drug Therapy, Combination; Eptifibatide; Female; Fibrinolytic Agents; Hemorrhage; Humans; Immunoglobulin Fab Fragments; Male; Peptides; Placebos; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Pregnancy; Ticlopidine; Tirofiban; Tyrosine | 2003 |
Abciximab pharmacodynamics are unaffected by antecedent therapy with other GPIIb/IIIa antagonists in non-human primates.
Topics: Abciximab; Animals; Antibodies, Monoclonal; Binding Sites, Antibody; Dose-Response Relationship, Drug; Drug Therapy, Combination; Eptifibatide; Female; Immunoglobulin Fab Fragments; Macaca fascicularis; Male; Peptides; Platelet Aggregation; Platelet Glycoprotein GPIIb-IIIa Complex; Protein Binding; Tirofiban; Tyrosine | 2002 |
Abciximab, eptifibatide, and tirofiban exhibit dose-dependent potencies to dissolve platelet aggregates.
Topics: Abciximab; Animals; Antibodies, Monoclonal; CHO Cells; Cricetinae; Dose-Response Relationship, Drug; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Peptides; Platelet Aggregation; Platelet Glycoprotein GPIIb-IIIa Complex; Tirofiban; Tyrosine | 2003 |
Use of platelet glycoprotein IIb/IIIa inhibitors and spontaneous pulmonary hemorrhage.
Topics: Abciximab; Aged; Antibodies, Monoclonal; Eptifibatide; Female; Hemorrhage; Humans; Immunoglobulin Fab Fragments; Incidence; Lung Diseases; Male; Michigan; Middle Aged; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Pulmonary Wedge Pressure; Tirofiban; Treatment Failure; Tyrosine; Ventricular Pressure | 2003 |
A propensity analysis of the impact of platelet glycoprotein IIb/IIIa inhibitor therapy on in-hospital outcomes after percutaneous coronary intervention.
Topics: Abciximab; Antibodies, Monoclonal; Coronary Disease; Coronary Thrombosis; Eptifibatide; Female; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Multivariate Analysis; Peptides; Platelet Glycoprotein GPIIb-IIIa Complex; Stents; Tirofiban; Treatment Outcome; Tyrosine | 2003 |
Deaths associated with platelet glycoprotein IIb/IIIa inhibitor treatment.
Topics: Abciximab; Adult; Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Death, Sudden; Eptifibatide; Female; Hemorrhage; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Myocardial Ischemia; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Risk Factors; Tirofiban; Tyrosine | 2003 |
Evaluation of glycoprotein IIb/IIIa inhibitors in carotid angioplasty and stenting.
Topics: Abciximab; Adult; Aged; Aged, 80 and over; Angioplasty; Antibodies, Monoclonal; Carotid Stenosis; Case-Control Studies; Eptifibatide; Female; Heparin; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Peptides; Platelet Glycoprotein GPIIb-IIIa Complex; Postoperative Complications; Retrospective Studies; Stents; Tirofiban; Treatment Outcome; Tyrosine | 2003 |
Adjunctive use of platelet glycoprotein IIb/IIIa inhibitors for carotid angioplasty and stent placement: time to say good bye?
Topics: Abciximab; Angioplasty; Antibodies, Monoclonal; Carotid Stenosis; Eptifibatide; Heparin; Humans; Immunoglobulin Fab Fragments; Peptides; Platelet Glycoprotein GPIIb-IIIa Complex; Postoperative Complications; Stents; Tirofiban; Treatment Outcome; Tyrosine | 2003 |
Cost and effectiveness of glycoprotein IIb/IIIa-receptor inhibitors in patients with acute myocardial infarction undergoing percutaneous coronary intervention.
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Case-Control Studies; Drug Costs; Eptifibatide; Female; Hospital Costs; Hospital Mortality; Humans; Immunoglobulin Fab Fragments; Length of Stay; Male; Middle Aged; Myocardial Infarction; Outcome and Process Assessment, Health Care; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Tirofiban; Treatment Outcome; Tyrosine; United States | 2003 |
Different effects of various anti-GPIIb-IIIa agents on shear-induced platelet activation and expression of procoagulant activity.
Topics: Abciximab; Antibodies, Monoclonal; Coagulants; Eptifibatide; Humans; Immunoglobulin Fab Fragments; P-Selectin; Particle Size; Peptides; Perfusion; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Factor 3; Platelet Glycoprotein GPIIb-IIIa Complex; Tirofiban; Tyrosine | 2003 |
Combined effects of mild hypothermia and glycoprotein IIb/IIIa antagonists on platelet-platelet and leukocyte-platelet aggregation.
Topics: Abciximab; Adult; Antibodies, Monoclonal; Eptifibatide; Female; Humans; Hypothermia, Induced; Immunoglobulin Fab Fragments; In Vitro Techniques; Leukocytes; Male; Middle Aged; Peptides; Platelet Adhesiveness; Platelet Aggregation; Platelet Glycoprotein GPIIb-IIIa Complex; Tirofiban; Tyrosine | 2003 |
Synergism of aspirin and heparin with a low-frequency non-invasive ultrasound system for augmentation of in-vitro clot lysis.
Topics: Adult; Aspirin; Drug Synergism; Drug Therapy, Combination; Eptifibatide; Heparin; Humans; In Vitro Techniques; Peptides; Platelet Glycoprotein GPIIb-IIIa Complex; Thrombolytic Therapy; Tirofiban; Tyrosine; Ultrasonic Therapy | 2003 |
[Efficacy and safety of treatment of acute ischemic stroke with glycoprotein IIb/IIIa receptor blocker in routine clinical practice].
Topics: Adult; Aged; Anticoagulants; Aspirin; Brain; Brain Ischemia; Carotid Arteries; Clopidogrel; Drug Therapy, Combination; Echocardiography, Transesophageal; Eptifibatide; Female; Heparin; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Retrospective Studies; Stroke; Ticlopidine; Tirofiban; Tomography, X-Ray Computed; Tyrosine; Ultrasonography, Doppler | 2004 |
Tirofiban and eptifibatide treatment of patients presenting with acute coronary syndrome with non-ST segment elevation.
Topics: Acute Disease; Aged; Aged, 80 and over; Biomarkers; Coronary Disease; Drug Utilization Review; Electrocardiography; Eptifibatide; Female; Formularies, Hospital as Topic; Humans; Inpatients; Male; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Practice Guidelines as Topic; Retrospective Studies; Tirofiban; Tyrosine | 2004 |
Glycoprotein IIb/IIIa inhibitors increase COAT-platelet production in vitro.
Topics: Antibodies, Monoclonal; Blood Platelets; Collagen; Eptifibatide; Fibrinogen; Humans; Isoxazoles; Peptides; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Sulfonamides; Thrombin; Tirofiban; Tyrosine | 2004 |
Distinct yet complementary mechanisms of heparin and glycoprotein IIb/IIIa inhibitors on platelet activation and aggregation: implications for restenosis during percutaneous coronary intervention.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Coronary Restenosis; Enoxaparin; Eptifibatide; Flow Cytometry; Hemostatics; Heparin; Humans; Immunoglobulin Fab Fragments; Peptides; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Platelet Membrane Glycoproteins; Receptors, G-Protein-Coupled; Thrombin; Tirofiban; Tyrosine | 2004 |
Ability of anti-glycoprotein IIb/IIIa agents to dissolve platelet thrombi formed on a collagen surface under blood flow conditions.
Topics: Abciximab; Adult; Antibodies, Monoclonal; Anticoagulants; Arginine; Blood Platelets; Collagen; Eptifibatide; Fibrinolytic Agents; Hemorheology; Humans; Immunoglobulin Fab Fragments; In Vitro Techniques; Peptides; Pipecolic Acids; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Sulfonamides; Thrombosis; Tirofiban; Tyrosine | 2004 |
Platelet function predicts myocardial damage in patients with acute myocardial infarction.
Topics: Abciximab; Adenosine Diphosphate; Aged; Antibodies, Monoclonal; Anticoagulants; Aspirin; Cardiovascular Agents; Clopidogrel; Collagen; Comorbidity; Eptifibatide; Female; Humans; Immunoglobulin Fab Fragments; Leukocyte Count; Male; Middle Aged; Myocardial Infarction; Myocardial Ischemia; Myocardium; Necrosis; Peptides; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Function Tests; Predictive Value of Tests; Prospective Studies; Ticlopidine; Tirofiban; Tyrosine; von Willebrand Factor | 2004 |
Evaluation of bleeding complications associated with glycoprotein IIb/IIIa inhibitors.
Topics: Abciximab; Aged; Antibodies, Monoclonal; Coronary Disease; Eptifibatide; Hemorrhage; Hospitals, Veterans; Humans; Immunoglobulin Fab Fragments; Incidence; Male; Middle Aged; Peptides; Platelet Glycoprotein GPIIb-IIIa Complex; Regression Analysis; Retrospective Studies; Risk Factors; Tirofiban; Tyrosine | 2004 |
Intra-arterial thrombolysis for acute ischemic stroke: preliminary experience with platelet glycoprotein IIb/IIIa inhibitors as adjunctive therapy.
Topics: Abciximab; Acute Disease; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Brain Ischemia; Chemotherapy, Adjuvant; Eptifibatide; Female; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Peptides; Platelet Glycoprotein GPIIb-IIIa Complex; Prospective Studies; Stroke; Thrombolytic Therapy; Tirofiban; Tyrosine | 2005 |
Comparison of ST-segment resolution with combined fibrinolytic and glycoprotein IIb/IIIa inhibitor therapy versus fibrinolytic alone (data from four clinical trials).
Topics: Abciximab; Acetates; Aged; Antibodies, Monoclonal; Clinical Trials as Topic; Drug Therapy, Combination; Electrocardiography; Eptifibatide; Female; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Myocardial Infarction; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Streptokinase; Survival Analysis; Thrombolytic Therapy; Tissue Plasminogen Activator; Treatment Outcome; Tyrosine | 2005 |
Is platelet function as measured by Thrombelastograph monitoring in whole blood affected by platelet inhibitors?
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Blood Platelets; Eptifibatide; Humans; Immunoglobulin Fab Fragments; In Vitro Techniques; Integrin beta3; Models, Theoretical; Peptides; Platelet Aggregation Inhibitors; Platelet Function Tests; Platelet Membrane Glycoprotein IIb; Point-of-Care Systems; Thrombelastography; Tirofiban; Tyrosine | 2005 |
Platelet endothelial aggregation receptor 1 (PEAR1), a novel epidermal growth factor repeat-containing transmembrane receptor, participates in platelet contact-induced activation.
Topics: Amino Acid Sequence; Animals; Biotin; Blood Platelets; Blotting, Western; Cell Communication; Cell Line; Cloning, Molecular; COS Cells; Cross-Linking Reagents; Cytoplasm; DNA, Complementary; Dose-Response Relationship, Drug; Electrophoresis, Polyacrylamide Gel; Endothelial Cells; Epidermal Growth Factor; Eptifibatide; Flow Cytometry; Humans; Immunoprecipitation; Mass Spectrometry; Molecular Sequence Data; Oligonucleotide Array Sequence Analysis; Peptides; Peroxidase; Phosphorylation; Platelet Activation; Platelet Aggregation; Platelet Glycoprotein GPIIb-IIIa Complex; Protein Binding; Protein Structure, Tertiary; Receptors, Cell Surface; Reverse Transcriptase Polymerase Chain Reaction; RNA; RNA, Messenger; Sequence Homology, Amino Acid; Serine; Signal Transduction; Threonine; Tissue Distribution; Transfection; Tyrosine | 2005 |
Differential inhibitory effects of platelet glycoprotein IIb/IIIa antagonists on aggregation induced by procoagulant agonists.
Topics: Abciximab; Adenosine Diphosphate; Antibodies, Monoclonal; C-Reactive Protein; Chromatography, Gel; Coagulants; Collagen; Dose-Response Relationship, Drug; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Models, Statistical; Peptides; Platelet Adhesiveness; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Platelet Membrane Glycoproteins; Tirofiban; Tyrosine | 2006 |
Variation in the ability of glycoprotein IIb-IIIa antagonists to exert and maintain their inhibitory effects on the binding of fibrinogen.
Topics: Adenosine Diphosphate; Aged; Binding, Competitive; Blood Platelets; Clopidogrel; Coronary Artery Disease; Data Interpretation, Statistical; Eptifibatide; Fibrinogen; Flow Cytometry; Fluorescein-5-isothiocyanate; Humans; Iodine Radioisotopes; Male; Peptide Fragments; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Receptors, Thrombin; Ticlopidine; Tirofiban; Tyrosine | 2005 |
Compatibility of argatroban with abciximab, eptifibatide, or tirofiban during simulated Y-site administration.
Topics: Abciximab; Antibodies, Monoclonal; Blood Platelets; Drug Contamination; Drug Incompatibility; Drug Stability; Drug Storage; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Peptides; Platelet Aggregation Inhibitors; Tirofiban; Tyrosine; United States | 2005 |
Choice of GPIIb/IIIa antagonist in percutaneous coronary intervention: how should economic criteria be factored in?
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Cost-Benefit Analysis; Diabetes Mellitus; Drug Costs; Eptifibatide; Hospital Costs; Humans; Immunoglobulin Fab Fragments; Myocardial Infarction; Peptides; Platelet Glycoprotein GPIIb-IIIa Complex; Time Factors; Tirofiban; Treatment Outcome; Tyrosine | 2005 |
Platelet glycoprotein IIb/IIIa inhibition as adjunctive therapy during primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction.
Topics: Abciximab; Acute Disease; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Chemotherapy, Adjuvant; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Myocardial Infarction; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Tirofiban; Tyrosine | 2005 |
Is platelet adhesion assay able to quantify drug-induced platelet dysfunction?
Topics: Abciximab; Aged; Antibodies, Monoclonal; Blood Platelet Disorders; Blood Platelets; Cell Separation; Clopidogrel; Dose-Response Relationship, Drug; Eptifibatide; Female; Fibrinogen; Flow Cytometry; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Peptides; Platelet Adhesiveness; Platelet Aggregation; Platelet Function Tests; Platelet Glycoprotein GPIIb-IIIa Complex; Polymers; Pyridines; Ticlopidine; Tirofiban; Tyrosine | 2005 |
The role of risk stratification in the decision to provide upstream versus selective glycoprotein IIb/IIIa inhibitors for acute coronary syndromes: a cost-effectiveness analysis.
Topics: Abciximab; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Cost-Benefit Analysis; Decision Support Techniques; Drug Costs; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Life Expectancy; Myocardial Infarction; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Quality-Adjusted Life Years; Risk Assessment; Risk Factors; Tirofiban; Tyrosine | 2006 |
Upstream/downstream glycoprotein IIb/IIIa in non-ST-segment elevation myocardial infarction.
Topics: Abciximab; Antibodies, Monoclonal; Cost-Benefit Analysis; Drug Costs; Electrocardiography; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Myocardial Infarction; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Tirofiban; Tyrosine | 2006 |
Variability in extent of platelet function inhibition after administration of optimal dose of glycoprotein IIb/IIIa receptor blockers in patients undergoing a high-risk percutaneous coronary intervention.
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Eptifibatide; Female; Humans; Immunoglobulin Fab Fragments; Male; Peptides; Platelet Aggregation; Platelet Glycoprotein GPIb-IX Complex; Platelet Glycoprotein GPIIb-IIIa Complex; Platelet Membrane Glycoproteins; Tirofiban; Tyrosine | 2006 |
In vitro effect of the potent poly(ADP-ribose) polymerase (PARP) inhibitor INO-1001 alone and in combination with aspirin, eptifibatide, tirofiban, enoxaparin or alteplase on haemostatic parameters.
Topics: Aspirin; Blood Coagulation; Blood Platelets; Dose-Response Relationship, Drug; Drug Combinations; Enzyme Inhibitors; Eptifibatide; Factor Xa Inhibitors; Female; Heparin; Humans; Indoles; Male; Partial Thromboplastin Time; Peptides; Platelet Aggregation Inhibitors; Poly(ADP-ribose) Polymerase Inhibitors; Tirofiban; Tissue Plasminogen Activator; Tyrosine | 2006 |
Tirofiban (Aggrastat) protects platelets and decreases platelet-granulocyte binding in an extracorporeal circulation model.
Topics: Aprotinin; Binding, Competitive; Biomarkers; Blood Platelets; Dipyridamole; Eptifibatide; Extracorporeal Circulation; Flow Cytometry; Granulocytes; Humans; Male; Milrinone; P-Selectin; Peptides; Phosphodiesterase Inhibitors; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Count; Platelet Glycoprotein GPIIb-IIIa Complex; Serine Proteinase Inhibitors; Tirofiban; Tyrosine | 2006 |
Conformation-specific blockade of the integrin GPIIb/IIIa: a novel antiplatelet strategy that selectively targets activated platelets.
Topics: Amino Acid Motifs; Animals; Antibodies; Bleeding Time; Blood Platelets; Carotid Artery Diseases; Chlorides; Complementarity Determining Regions; Eptifibatide; Ferric Compounds; Fibrinogen; Fibrinolytic Agents; Humans; Mice; Mice, Inbred C57BL; Molecular Conformation; Peptides; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Thrombosis; Tirofiban; Tyrosine | 2006 |
Complementary effects of sirolimus-eluting stents and glycoprotein IIb/IIIa inhibitors for percutaneous coronary intervention in diabetic patients: one-year follow up of a single-centre registry.
Topics: Coronary Restenosis; Diabetic Angiopathies; Disease-Free Survival; Drug Combinations; Drug Implants; Eptifibatide; Follow-Up Studies; Humans; Immunosuppressive Agents; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Sirolimus; Stents; Tirofiban; Tyrosine | 2006 |
Sex differences in major bleeding with glycoprotein IIb/IIIa inhibitors: results from the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA guidelines) initiative.
Topics: Acute Disease; Adult; Angina, Unstable; Blood Transfusion; Cerebral Hemorrhage; Creatinine; Disease Susceptibility; Dose-Response Relationship, Drug; Eptifibatide; Glomerular Filtration Rate; Hemorrhage; Hemorrhagic Disorders; Humans; Kidney Diseases; Myocardial Infarction; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Practice Guidelines as Topic; Registries; Sex Characteristics; Tirofiban; Tyrosine | 2006 |
Platelet microparticle formation and thrombin generation under high shear are effectively suppressed by a monoclonal antibody against GPIba.
Topics: Abciximab; Annexin A5; Antibodies, Monoclonal; Binding Sites, Antibody; Blood Platelets; Dose-Response Relationship, Drug; Epitope Mapping; Eptifibatide; Flow Cytometry; Humans; Immunoglobulin Fab Fragments; In Vitro Techniques; Peptides; Phosphatidylserines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Platelet Glycoprotein GPIb-IX Complex; Platelet Glycoprotein GPIIb-IIIa Complex; Stress, Mechanical; Thrombin; Tirofiban; Tyrosine; von Willebrand Factor | 2006 |
AlphaIIbbeta3 priming and clustering by orally active and intravenous integrin antagonists.
Topics: Administration, Oral; Alanine; Amidines; Binding, Competitive; Blood Platelets; Dimerization; Dose-Response Relationship, Drug; Eptifibatide; Female; Fibrinogen; Humans; In Vitro Techniques; Injections, Intravenous; Intercellular Signaling Peptides and Proteins; Isoxazoles; Kinetics; Male; Models, Molecular; Peptides; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Function Tests; Platelet Glycoprotein GPIIb-IIIa Complex; Protein Binding; Protein Conformation; Pyrrolidines; Reference Values; Structure-Activity Relationship; Tirofiban; Tyrosine | 2007 |
Bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitors in drug-eluting stent implantations in the absence of acute myocardial infarction: clinical and economic results.
Topics: Abciximab; Aged; Antibodies, Monoclonal; Anticoagulants; Coronary Artery Disease; Costs and Cost Analysis; Drug Delivery Systems; Drug Therapy, Combination; Eptifibatide; Female; Heparin; Hirudins; Humans; Immunoglobulin Fab Fragments; Immunosuppressive Agents; Length of Stay; Male; Middle Aged; Myocardial Infarction; Paclitaxel; Peptide Fragments; Peptides; Platelet Glycoprotein GPIIb-IIIa Complex; Recombinant Proteins; Retrospective Studies; Sirolimus; Stents; Tirofiban; Treatment Outcome; Tyrosine | 2007 |
Timing of glycoprotein IIb/IIIa inhibitor use and outcomes among patients with non-ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention (results from CRUSADE).
Topics: Abciximab; Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Combined Modality Therapy; Eptifibatide; Female; Hospital Mortality; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Myocardial Infarction; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Time Factors; Tirofiban; Treatment Outcome; Tyrosine; United States | 2007 |
Glycoprotein IIb/IIIa antagonists during carotid artery stenting: results from the carotid artery stenting (CAS) registry of the Arbeitsgemeinschaft Leitende Kardiologische Krankenhausärzte (ALKK).
Topics: Abciximab; Aged; Antibodies, Monoclonal; Carotid Stenosis; Eptifibatide; Female; Humans; Immunoglobulin Fab Fragments; Logistic Models; Male; Middle Aged; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Registries; Stents; Tirofiban; Tyrosine | 2007 |
Beta2-integrins and acquired glycoprotein IIb/IIIa (GPIIb/IIIa) receptors cooperate in NF-kappaB activation of human neutrophils.
Topics: Abciximab; Antibodies, Monoclonal; Blood Platelets; CD18 Antigens; Eptifibatide; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Immunoglobulin Fab Fragments; Integrin beta3; Neutrophils; NF-kappa B; Peptides; Phosphatidylinositol 3-Kinases; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Platelet Membrane Glycoprotein IIb; Tirofiban; Tumor Necrosis Factor-alpha; Tyrosine | 2007 |
High-dose tirofiban administered as bolus-only during percutaneous coronary intervention.
Topics: Aged; Angioplasty, Balloon, Coronary; Eptifibatide; Female; Humans; Injections, Intravenous; Male; Middle Aged; Myocardial Infarction; Peptides; Platelet Aggregation Inhibitors; Retrospective Studies; Tirofiban; Treatment Outcome; Tyrosine | 2008 |
Real-world safety and efficacy of glycoprotein IIb/IIIa inhibitors during percutaneous coronary intervention.
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Coronary Artery Disease; Eptifibatide; Female; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Retrospective Studies; Tirofiban; Tyrosine | 2008 |
Species differences in small molecule binding to alpha IIb beta 3 are the result of sequence differences in 2 loops of the alpha IIb beta propeller.
Topics: Adenosine Diphosphate; Amino Acid Sequence; Animals; Cell Line; Conserved Sequence; Cricetinae; Eptifibatide; Fibrinogen; Humans; Mice; Molecular Sequence Data; Peptides; Platelet Aggregation; Platelet Glycoprotein GPIIb-IIIa Complex; Protein Binding; Rats; Recombinant Proteins; Sequence Alignment; Tirofiban; Tyrosine | 2009 |
Long-term mortality after bolus-only administration of abciximab, eptifibatide, or tirofiban during percutaneous coronary intervention.
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Coronary Artery Disease; Eptifibatide; Female; Hemorrhage; Hospital Mortality; Humans; Immunoglobulin Fab Fragments; Injections, Intravenous; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Odds Ratio; Peptides; Platelet Aggregation Inhibitors; Proportional Hazards Models; Retrospective Studies; Risk Assessment; Stents; Time Factors; Tirofiban; Treatment Outcome; Tyrosine | 2009 |
The benefits and risks of abciximab, eptifibatide, or tirofiban during PCI: class effects or do they differ?
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Coronary Artery Disease; Eptifibatide; Hemorrhage; Hospital Mortality; Humans; Immunoglobulin Fab Fragments; Injections, Intravenous; Myocardial Infarction; Peptides; Platelet Aggregation Inhibitors; Risk Assessment; Stents; Time Factors; Tirofiban; Treatment Outcome; Tyrosine | 2009 |
The benefits of platelet glycoprotein IIb/IIIa receptor inhibition during primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: drug-specific or class effect?
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Eptifibatide; Fibrinolytic Agents; Humans; Immunoglobulin Fab Fragments; Myocardial Infarction; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Tirofiban; Tyrosine | 2009 |
Integrin priming dynamics: mechanisms of integrin antagonist-promoted alphaIIbbeta3:PAC-1 molecular recognition.
Topics: Amidines; Dual Specificity Phosphatase 2; Eptifibatide; Integrins; Intercellular Signaling Peptides and Proteins; Isoxazoles; Models, Molecular; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Protein Binding; Thermodynamics; Tirofiban; Tyrosine | 2009 |
Characterization of static adhesion of human platelets in plasma to protein surfaces in microplates.
Topics: Abciximab; Albumins; Antibodies, Monoclonal; Blood Platelets; Collagen; Eptifibatide; Fibrinogen; Humans; Immunoglobulin Fab Fragments; Peptides; Plasma; Platelet Adhesiveness; Platelet Aggregation; Proteins; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2; Thromboxane A2; Tirofiban; Tyrosine | 2009 |
The GPIIbIIIa antagonist drugs eptifibatide and tirofiban do not induce activation of apoptosis executioner caspase-3 in resting platelets but inhibit caspase-3 activation in platelets stimulated with thrombin or calcium ionophore A23187.
Topics: Apoptosis; Blood Platelets; Calcimycin; Caspase 3; Coagulants; Enzyme Activation; Eptifibatide; Flow Cytometry; Humans; Ionophores; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Thrombin; Tirofiban; Tyrosine | 2009 |
Antibodies causing thrombocytopenia in patients treated with RGD-mimetic platelet inhibitors recognize ligand-specific conformers of αIIb/β3 integrin.
Topics: Animals; Antibodies; CHO Cells; Cricetinae; Cricetulus; Eptifibatide; Humans; Ligands; Mice; Mice, Inbred BALB C; Models, Biological; Oligopeptides; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Protein Binding; Protein Conformation; Rats; Substrate Specificity; Thrombocytopenia; Tirofiban; Tyrosine | 2012 |
Impact of preprocedural TIMI flow on myocardial perfusion, distal embolization and mortality in patients with ST-segment elevation myocardial infarction treated by primary angioplasty and glycoprotein IIb/IIIa inhibitors.
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Combined Modality Therapy; Electrocardiography; Eptifibatide; Female; Follow-Up Studies; Humans; Immunoglobulin Fab Fragments; Incidence; Male; Middle Aged; Myocardial Infarction; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Regional Blood Flow; Regression Analysis; Retrospective Studies; Risk Factors; Survival Rate; Thrombosis; Tirofiban; Treatment Outcome; Tyrosine | 2012 |
PlA(1)/PlA(2) polymorphism does not influence response to Gp IIb-IIIa inhibitors in patients undergoing coronary angioplasty.
Topics: Abciximab; Aged; Amino Acid Substitution; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Blood Platelets; Drug Administration Schedule; Eptifibatide; Female; Humans; Immunoglobulin Fab Fragments; Leucine; Male; Middle Aged; Myocardial Infarction; Peptides; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Polymorphism, Genetic; Proline; Tirofiban; Treatment Outcome; Tyrosine | 2013 |
An effect of glycoprotein IIb/IIIa inhibitors on the kinetics of red blood cells aggregation.
Topics: Adult; Antibodies, Monoclonal; Blood Platelets; Cell Communication; Eptifibatide; Erythrocyte Aggregation; Erythrocytes; Fibrinogen; Humans; Kinetics; Ligands; Optics and Photonics; Peptide Fragments; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Tirofiban; Tyrosine; Young Adult | 2014 |
Perioperative management of antiplatelet therapy in patients with coronary stents undergoing cardiac and non-cardiac surgery: a consensus document from Italian cardiological, surgical and anaesthesiological societies.
Topics: Anesthesiology; Aspirin; Cardiac Surgical Procedures; Cardiology; Clopidogrel; Eptifibatide; Hemorrhage; Humans; Italy; Myocardial Ischemia; Peptides; Perioperative Care; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Risk Assessment; Societies, Medical; Stents; Surgical Procedures, Operative; Thoracic Surgery; Ticlopidine; Tirofiban; Tyrosine | 2014 |
Gene mutations of platelet glycoproteins and response to tirofiban in acute coronary syndrome.
Topics: Abciximab; Acute Coronary Syndrome; Aged; Angina, Unstable; Antibodies, Monoclonal; Eptifibatide; Female; Genotype; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Mutation; Peptides; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Platelet Membrane Glycoproteins; Polymerase Chain Reaction; Prospective Studies; Tirofiban; Tyrosine | 2016 |
A Naphthalenic Derivative ND-1 Inhibits Thrombus Formation by Interfering the Binding of Fibrinogen to Integrin
Topics: Abciximab; Animals; Antibodies, Monoclonal; Cardiovascular Diseases; Disease Models, Animal; Eptifibatide; Fibrinogen; Hemorrhage; Humans; Immunoglobulin Fab Fragments; Integrin alpha2; Integrin beta3; Mice; Naphthalenes; Peptides; Platelet Aggregation; Rats; Thrombocytopenia; Thrombosis; Tirofiban; Tyrosine | 2016 |
Inhibition of Src but not Syk causes weak reversal of GPVI-mediated platelet aggregation measured by light transmission aggregometry.
Topics: Agammaglobulinaemia Tyrosine Kinase; Apyrase; Blood Platelets; Collagen; Eptifibatide; Fluorescein-5-isothiocyanate; Humans; Indomethacin; Intracellular Signaling Peptides and Proteins; Lectins, C-Type; Ligands; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Platelet Membrane Glycoproteins; Protein-Tyrosine Kinases; src-Family Kinases; Syk Kinase; Tyrosine | 2022 |